[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fHKJoLPP3h7--w_fP8Rr5apadEcGN0X7O6H8Sq5U9ay8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"Rush University Medical Center",[4],392,false,84,15,213904,27,290,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Osteoarthritis",13,{"name":18,"count":19},"Parkinson Disease",11,{"name":21,"count":22},"Obesity",9,{"name":24,"count":25},"Total Knee Arthroplasty",8,{"name":27,"count":28},"Hypertension",7,{"name":30,"count":31},"Asthma",6,{"name":33,"count":34},"Knee Osteoarthritis",5,{"name":36,"count":34},"Cardiovascular Diseases",[38,43,48,53,58,63,68,73,78,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04744883","Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain","2024-11-29","Naloxone",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06643299","Probiotic Use for Recovery Enhancement From Long COVID-19","2026-05","Probiotic Agent",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05097976","Medrol Dosepak for Outpatient Total Knee Arthroplasty","2026-05-30","Methylprednisolone",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06489431","Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement","2026-05-31","Chlorhexidine",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT00577200","Safety of Driving After Minor Surgery With Monitored Anesthesia Care","2026-11","Midazolam",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT02582489","Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy","2026-11-30","Bone Marrow Aspirate Concentrate",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05864053","(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain","2026-12","Ketamine",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06894719","Oral Tranexamic Acid After Total Knee Arthroplasty","2026-12-01","tranexamic acid Oral-Short Arm",{"nctId":79,"briefTitle":80,"date":76,"intervention":81},"NCT03849443","Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery","Tranexamic Acid Injectable Product",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT07487246","Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement","2027-04-30","Ketorolac",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,122,140,158,187,210,228,246,330,355,373,391,452,505,532,561,579,597,619,637,655,675,700,724,742,760,785,806,852,889,924,949,967,992,1017,1044,1062,1087,1105,1134,1152,1178,1204,1222,1247,1274,1300,1318,1343,1361,1387,1411,1429,1453,1471,1498,1516,1534,1558,1585,1603,1629,1653,1671,1689,1707,1731,1758,1776,1798,1822,1846,1870,1888,1906,1924,1942,1960,1978,1996,2014,2032,2050,2068,2086,2112,2130,2148,2166,2191,2220,2238,2256,2285,2310,2328,2352,2394,2416,2438,2473,2496,2522,2546,2571,2595,2613,2631,2649,2667,2685,2703,2721,2739,2764,2782,2807,2834,2858,2882,2907,2925,2943,2961,2979,2997,3015,3038,3064,3082,3105,3123,3146,3172,3198,3221,3245,3269,3287,3313,3331,3349,3381,3408,3426,3451,3469,3493,3519,3543,3561,3587,3605,3631,3649,3674,3692,3720,3738,3762,3780,3804,3830,3854,3879,3897],{"intervention":62,"totalTrials":96,"cells":97},1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":120},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":61},[109],{"nctId":59,"briefTitle":60,"status":110,"phases":111,"primaryCompletion":61,"completion":71,"start":112,"enrollment":113,"conditions":114,"interventions":117},"ACTIVE_NOT_RECRUITING",[92],"2008-01",625,[115,116],"Minor Surgical Procedures With Monitored Anesthesia Care","Driving Performance After Minor Ambulatory Surgery",[62,118,119],"Sufentanil","Propofol",{"trials":121,"activeCount":100},[],{"intervention":118,"totalTrials":96,"cells":123},{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":132,"NA":138},{"trials":125,"activeCount":100},[],{"trials":127,"activeCount":100},[],{"trials":129,"activeCount":100},[],{"trials":131,"activeCount":100},[],{"trials":133,"activeCount":96,"soonestReadout":61},[134],{"nctId":59,"briefTitle":60,"status":110,"phases":135,"primaryCompletion":61,"completion":71,"start":112,"enrollment":113,"conditions":136,"interventions":137},[92],[115,116],[62,118,119],{"trials":139,"activeCount":100},[],{"intervention":119,"totalTrials":96,"cells":141},{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":156},{"trials":143,"activeCount":100},[],{"trials":145,"activeCount":100},[],{"trials":147,"activeCount":100},[],{"trials":149,"activeCount":100},[],{"trials":151,"activeCount":96,"soonestReadout":61},[152],{"nctId":59,"briefTitle":60,"status":110,"phases":153,"primaryCompletion":61,"completion":71,"start":112,"enrollment":113,"conditions":154,"interventions":155},[92],[115,116],[62,118,119],{"trials":157,"activeCount":100},[],{"intervention":159,"totalTrials":96,"cells":160},"Losartan",{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":167,"PHASE4":169,"NA":185},{"trials":162,"activeCount":100},[],{"trials":164,"activeCount":100},[],{"trials":166,"activeCount":100},[],{"trials":168,"activeCount":100},[],{"trials":170,"activeCount":96,"soonestReadout":176},[171],{"nctId":172,"briefTitle":173,"status":174,"phases":175,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":184},"NCT07135687","Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction","NOT_YET_RECRUITING",[92],"2028-10","2028-12","2026-08",144,[181,182,183],"ACL Injury","ACL Reconstruction","Scar Formation",[159],{"trials":186,"activeCount":100},[],{"intervention":77,"totalTrials":96,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":208},{"trials":190,"activeCount":100},[],{"trials":192,"activeCount":100},[],{"trials":194,"activeCount":100},[],{"trials":196,"activeCount":100},[],{"trials":198,"activeCount":96,"soonestReadout":76},[199],{"nctId":74,"briefTitle":75,"status":174,"phases":200,"primaryCompletion":76,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":205},[92],"2027-05-01","2026-06-01",351,[24],[77,206,207],"tranexamic acid Oral-Long Arm","Control group placebo",{"trials":209,"activeCount":100},[],{"intervention":206,"totalTrials":96,"cells":211},{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":218,"PHASE4":220,"NA":226},{"trials":213,"activeCount":100},[],{"trials":215,"activeCount":100},[],{"trials":217,"activeCount":100},[],{"trials":219,"activeCount":100},[],{"trials":221,"activeCount":96,"soonestReadout":76},[222],{"nctId":74,"briefTitle":75,"status":174,"phases":223,"primaryCompletion":76,"completion":201,"start":202,"enrollment":203,"conditions":224,"interventions":225},[92],[24],[77,206,207],{"trials":227,"activeCount":100},[],{"intervention":207,"totalTrials":96,"cells":229},{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":238,"NA":244},{"trials":231,"activeCount":100},[],{"trials":233,"activeCount":100},[],{"trials":235,"activeCount":100},[],{"trials":237,"activeCount":100},[],{"trials":239,"activeCount":96,"soonestReadout":76},[240],{"nctId":74,"briefTitle":75,"status":174,"phases":241,"primaryCompletion":76,"completion":201,"start":202,"enrollment":203,"conditions":242,"interventions":243},[92],[24],[77,206,207],{"trials":245,"activeCount":100},[],{"intervention":52,"totalTrials":31,"cells":247},{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":296,"NA":316},{"trials":249,"activeCount":100},[],{"trials":251,"activeCount":100},[],{"trials":253,"activeCount":100},[],{"trials":255,"activeCount":100},[256,273,285],{"nctId":257,"briefTitle":258,"status":259,"phases":260,"primaryCompletion":261,"completion":261,"start":262,"enrollment":100,"conditions":263,"interventions":271},"NCT03327272","Impact of Local Steroid Application in Extreme Lateral Lumbar Interbody Fusion","WITHDRAWN",[91],"2020-07-24","2018-05-22",[264,265,266,267,268,269,270],"Stenosis","Herniated Nucleus Pulposus","Degenerative Disc Disease","Spondylosis","Myelopathy","Radiculopathy","Myeloradiculopathy",[52,272],"Saline",{"nctId":274,"briefTitle":275,"status":276,"phases":277,"primaryCompletion":278,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":283},"NCT03308084","Use of Local Intraoperative Steroid in MIS TLIF","COMPLETED",[91],"2019-05-03","2015-11-13",105,[282],"Dysphasia",[52,284],"Dexamethasone",{"nctId":286,"briefTitle":287,"status":276,"phases":288,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":295},"NCT03311425","Effect of Local Intraoperative Steroid on Dysphagia After ACDF",[91],"2017-06-27","2019-07-20","2014-08-01",140,[294],"Dysphagia",[52,284],{"trials":297,"activeCount":96,"soonestReadout":51},[298,305],{"nctId":49,"briefTitle":50,"status":299,"phases":300,"primaryCompletion":51,"completion":71,"start":301,"enrollment":302,"conditions":303,"interventions":304},"RECRUITING",[92],"2022-03-01",420,[24],[52],{"nctId":306,"briefTitle":307,"status":308,"phases":309,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":315},"NCT05113901","Medrol Dosepak Taper for Delayed Post-op Recovery After TKA","TERMINATED",[92],"2022-07-01","2022-07-25","2022-03-03",4,[24],[52],{"trials":317,"activeCount":100},[318],{"nctId":319,"briefTitle":320,"status":308,"phases":321,"primaryCompletion":322,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":328},"NCT02591953","Prospective Clinical Analysis of Ultrasound-guided Biceps Corticosteroid Injections",[93],"2019-05","2015-11",22,[326,327],"Biceps Tendonitis","Injection",[52,329],"Lidocaine 1%",{"intervention":57,"totalTrials":96,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":338,"PHASE4":351,"NA":353},{"trials":333,"activeCount":100},[],{"trials":335,"activeCount":100},[],{"trials":337,"activeCount":100},[],{"trials":339,"activeCount":96,"soonestReadout":56},[340],{"nctId":54,"briefTitle":55,"status":110,"phases":341,"primaryCompletion":56,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":348},[91],"2027-12-31","2023-12-04",200,[346,347],"Erectile Dysfunction","Penile Prosthesis; Complications, Infection or Inflammation",[57,349,350],"Gentamicin","Rifampin",{"trials":352,"activeCount":100},[],{"trials":354,"activeCount":100},[],{"intervention":349,"totalTrials":96,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":369,"NA":371},{"trials":358,"activeCount":100},[],{"trials":360,"activeCount":100},[],{"trials":362,"activeCount":100},[],{"trials":364,"activeCount":96,"soonestReadout":56},[365],{"nctId":54,"briefTitle":55,"status":110,"phases":366,"primaryCompletion":56,"completion":342,"start":343,"enrollment":344,"conditions":367,"interventions":368},[91],[346,347],[57,349,350],{"trials":370,"activeCount":100},[],{"trials":372,"activeCount":100},[],{"intervention":350,"totalTrials":96,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":381,"PHASE4":387,"NA":389},{"trials":376,"activeCount":100},[],{"trials":378,"activeCount":100},[],{"trials":380,"activeCount":100},[],{"trials":382,"activeCount":96,"soonestReadout":56},[383],{"nctId":54,"briefTitle":55,"status":110,"phases":384,"primaryCompletion":56,"completion":342,"start":343,"enrollment":344,"conditions":385,"interventions":386},[91],[346,347],[57,349,350],{"trials":388,"activeCount":100},[],{"trials":390,"activeCount":100},[],{"intervention":272,"totalTrials":34,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":420,"PHASE4":426,"NA":428},{"trials":394,"activeCount":100},[],{"trials":396,"activeCount":100},[],{"trials":398,"activeCount":419,"soonestReadout":71},[399,407],{"nctId":69,"briefTitle":70,"status":299,"phases":400,"primaryCompletion":71,"completion":71,"start":401,"enrollment":402,"conditions":403,"interventions":405},[89,90],"2024-09-19",25,[404],"Pain, Neuropathic",[72,406,272],"(2R,6R)-hydroxynorketamine",{"nctId":83,"briefTitle":84,"status":174,"phases":408,"primaryCompletion":85,"completion":85,"start":409,"enrollment":410,"conditions":411,"interventions":416},[90],"2026-05-01",76,[412,413,414,415],"Pain Management","Abortion","Second Trimester Abortion","Dilation and Evacuation",[86,417,418,272],"oral ibuprofen","Lidocaine HCl 1%",2,{"trials":421,"activeCount":100},[422],{"nctId":257,"briefTitle":258,"status":259,"phases":423,"primaryCompletion":261,"completion":261,"start":262,"enrollment":100,"conditions":424,"interventions":425},[91],[264,265,266,267,268,269,270],[52,272],{"trials":427,"activeCount":100},[],{"trials":429,"activeCount":100},[430,442],{"nctId":431,"briefTitle":432,"status":259,"phases":433,"primaryCompletion":434,"completion":435,"start":436,"enrollment":100,"conditions":437,"interventions":440},"NCT02693444","Comparison of Strength and Constant Score Pre- and Post-Subacromial Injection for Full Thickness Rotator Cuff Tears",[93],"2017-02-28","2017-04-27","2016-03-02",[438,439],"Rotator Cuff","Subacromial Impingement Syndrome",[441,272],"Lidocaine",{"nctId":443,"briefTitle":444,"status":259,"phases":445,"primaryCompletion":446,"completion":446,"start":447,"enrollment":100,"conditions":448,"interventions":450},"NCT05656170","Stellate Ganglion to Prevent Atrial Fibrillation",[93],"2024-04","2023-10-01",[449],"Atrial Fibrillation New Onset",[451,272],"Bupivacain",{"intervention":86,"totalTrials":453,"cells":454},3,{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":465,"PHASE4":489,"NA":503},{"trials":456,"activeCount":100},[],{"trials":458,"activeCount":100},[],{"trials":460,"activeCount":96,"soonestReadout":85},[461],{"nctId":83,"briefTitle":84,"status":174,"phases":462,"primaryCompletion":85,"completion":85,"start":409,"enrollment":410,"conditions":463,"interventions":464},[90],[412,413,414,415],[86,417,418,272],{"trials":466,"activeCount":100},[467],{"nctId":468,"briefTitle":469,"status":259,"phases":470,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":473,"interventions":476},"NCT03586934","Multimodal Analgesia in Shoulder Arthroplasty",[91],"2019-06-01","2018-06-01",[474,475],"Shoulder Pain","Opioid Use",[477,478,479,480,86,481,482,483,484,485,486,487,488],"Acetaminophen","Celecoxib 200mg","Celecoxib 400 mg","Ropivacaine","Acetaminophen Injectable Product","Oxycodone","Tramadol","Morphine Injectable Solution","hydrocodone bitartrate and acetaminophen","Morphine","Oxycodone Hydrochloride","Meloxicam",{"trials":490,"activeCount":100},[491],{"nctId":492,"briefTitle":493,"status":259,"phases":494,"primaryCompletion":495,"completion":495,"start":496,"enrollment":100,"conditions":497,"interventions":499},"NCT03119038","Efficacy of Intraoperative Injections on Postoperative Pain Control During Total Hip Replacement",[92],"2022-10-25","2016-04-30",[15,498],"Degenerative Joint Disease",[500,501,480,86,502],"Bupivicaine + epinephrine","Bupivacaine","Clonidine",{"trials":504,"activeCount":100},[],{"intervention":506,"totalTrials":96,"cells":507},"Esomeprazole 40 mg",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":526,"PHASE4":528,"NA":530},{"trials":509,"activeCount":100},[],{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":96,"soonestReadout":518},[514],{"nctId":515,"briefTitle":516,"status":299,"phases":517,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":525},"NCT06120803","Esomeprazole and Radiation Induced Esophagitis",[90],"2027-12-30","2028-06-30","2024-03-01",48,[523,524],"Radiation Esophagitis","Locally Advanced Lung Carcinoma",[506],{"trials":527,"activeCount":100},[],{"trials":529,"activeCount":100},[],{"trials":531,"activeCount":100},[],{"intervention":533,"totalTrials":96,"cells":534},"Nicotine Replacement Therapy (NRT) Sampling",{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":555,"PHASE4":557,"NA":559},{"trials":536,"activeCount":100},[],{"trials":538,"activeCount":100},[],{"trials":540,"activeCount":96,"soonestReadout":545},[541],{"nctId":542,"briefTitle":543,"status":299,"phases":544,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":554},"NCT05513872","Overcoming Nicotine Dependence to Enable Quitting",[89,90],"2027-08-30","2023-03-24",780,[549,550,551,552,553],"Tobacco Use","Smoking Cessation","Smoking Behaviors","Nicotine Dependence","Nicotine Withdrawal",[533],{"trials":556,"activeCount":100},[],{"trials":558,"activeCount":100},[],{"trials":560,"activeCount":100},[],{"intervention":72,"totalTrials":96,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":564,"activeCount":100},[],{"trials":566,"activeCount":100},[],{"trials":568,"activeCount":96,"soonestReadout":71},[569],{"nctId":69,"briefTitle":70,"status":299,"phases":570,"primaryCompletion":71,"completion":71,"start":401,"enrollment":402,"conditions":571,"interventions":572},[89,90],[404],[72,406,272],{"trials":574,"activeCount":100},[],{"trials":576,"activeCount":100},[],{"trials":578,"activeCount":100},[],{"intervention":406,"totalTrials":96,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":591,"PHASE4":593,"NA":595},{"trials":582,"activeCount":100},[],{"trials":584,"activeCount":100},[],{"trials":586,"activeCount":96,"soonestReadout":71},[587],{"nctId":69,"briefTitle":70,"status":299,"phases":588,"primaryCompletion":71,"completion":71,"start":401,"enrollment":402,"conditions":589,"interventions":590},[89,90],[404],[72,406,272],{"trials":592,"activeCount":100},[],{"trials":594,"activeCount":100},[],{"trials":596,"activeCount":100},[],{"intervention":47,"totalTrials":96,"cells":598},{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":613,"PHASE4":615,"NA":617},{"trials":600,"activeCount":100},[],{"trials":602,"activeCount":100},[],{"trials":604,"activeCount":96,"soonestReadout":46},[605],{"nctId":44,"briefTitle":45,"status":110,"phases":606,"primaryCompletion":46,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":612},[90],"2026-07","2025-05-13",180,[611],"Post-Acute COVID-19 Syndrome",[47],{"trials":614,"activeCount":100},[],{"trials":616,"activeCount":100},[],{"trials":618,"activeCount":100},[],{"intervention":417,"totalTrials":96,"cells":620},{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":631,"PHASE4":633,"NA":635},{"trials":622,"activeCount":100},[],{"trials":624,"activeCount":100},[],{"trials":626,"activeCount":96,"soonestReadout":85},[627],{"nctId":83,"briefTitle":84,"status":174,"phases":628,"primaryCompletion":85,"completion":85,"start":409,"enrollment":410,"conditions":629,"interventions":630},[90],[412,413,414,415],[86,417,418,272],{"trials":632,"activeCount":100},[],{"trials":634,"activeCount":100},[],{"trials":636,"activeCount":100},[],{"intervention":418,"totalTrials":96,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":649,"PHASE4":651,"NA":653},{"trials":640,"activeCount":100},[],{"trials":642,"activeCount":100},[],{"trials":644,"activeCount":96,"soonestReadout":85},[645],{"nctId":83,"briefTitle":84,"status":174,"phases":646,"primaryCompletion":85,"completion":85,"start":409,"enrollment":410,"conditions":647,"interventions":648},[90],[412,413,414,415],[86,417,418,272],{"trials":650,"activeCount":100},[],{"trials":652,"activeCount":100},[],{"trials":654,"activeCount":100},[],{"intervention":42,"totalTrials":96,"cells":656},{"EARLY_PHASE1":657,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":658,"activeCount":96,"soonestReadout":41},[659],{"nctId":39,"briefTitle":40,"status":110,"phases":660,"primaryCompletion":41,"completion":202,"start":661,"enrollment":292,"conditions":662,"interventions":664},[88],"2020-08-15",[663],"Chronic Low-back Pain",[42],{"trials":666,"activeCount":100},[],{"trials":668,"activeCount":100},[],{"trials":670,"activeCount":100},[],{"trials":672,"activeCount":100},[],{"trials":674,"activeCount":100},[],{"intervention":676,"totalTrials":96,"cells":677},"Stellate Ganglion Block",{"EARLY_PHASE1":678,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":679,"activeCount":96,"soonestReadout":684},[680],{"nctId":681,"briefTitle":682,"status":299,"phases":683,"primaryCompletion":684,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":689},"NCT06570213","Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD",[88],"2029-12-31","2026-04-01",270,[688],"PTSD",[676],{"trials":691,"activeCount":100},[],{"trials":693,"activeCount":100},[],{"trials":695,"activeCount":100},[],{"trials":697,"activeCount":100},[],{"trials":699,"activeCount":100},[],{"intervention":81,"totalTrials":96,"cells":701},{"EARLY_PHASE1":702,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":720,"NA":722},{"trials":703,"activeCount":96,"soonestReadout":76},[704],{"nctId":79,"briefTitle":80,"status":299,"phases":705,"primaryCompletion":76,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":711},[88],"2027-01-01","2019-08-26",604,[710],"Open Posterior Thoracolumbar Spinal Fusion Procedure",[81,712,713],"Vitamin C 250 MG Oral","Tranexamic Acid 650Mg",{"trials":715,"activeCount":100},[],{"trials":717,"activeCount":100},[],{"trials":719,"activeCount":100},[],{"trials":721,"activeCount":100},[],{"trials":723,"activeCount":100},[],{"intervention":712,"totalTrials":96,"cells":725},{"EARLY_PHASE1":726,"PHASE1":732,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":740},{"trials":727,"activeCount":96,"soonestReadout":76},[728],{"nctId":79,"briefTitle":80,"status":299,"phases":729,"primaryCompletion":76,"completion":706,"start":707,"enrollment":708,"conditions":730,"interventions":731},[88],[710],[81,712,713],{"trials":733,"activeCount":100},[],{"trials":735,"activeCount":100},[],{"trials":737,"activeCount":100},[],{"trials":739,"activeCount":100},[],{"trials":741,"activeCount":100},[],{"intervention":713,"totalTrials":96,"cells":743},{"EARLY_PHASE1":744,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":745,"activeCount":96,"soonestReadout":76},[746],{"nctId":79,"briefTitle":80,"status":299,"phases":747,"primaryCompletion":76,"completion":706,"start":707,"enrollment":708,"conditions":748,"interventions":749},[88],[710],[81,712,713],{"trials":751,"activeCount":100},[],{"trials":753,"activeCount":100},[],{"trials":755,"activeCount":100},[],{"trials":757,"activeCount":100},[],{"trials":759,"activeCount":100},[],{"intervention":761,"totalTrials":96,"cells":762},"Corticosteroid injections",{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":764,"activeCount":100},[],{"trials":766,"activeCount":100},[],{"trials":768,"activeCount":100},[],{"trials":770,"activeCount":100},[],{"trials":772,"activeCount":100},[],{"trials":774,"activeCount":96,"soonestReadout":342},[775],{"nctId":776,"briefTitle":777,"status":299,"phases":778,"primaryCompletion":342,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":784},"NCT05985785","Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection",[93],"2028-03-31","2022-07-19",100,[783],"Osteoarthritis of the Knee",[761],{"intervention":67,"totalTrials":96,"cells":786},{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":791,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":788,"activeCount":100},[],{"trials":790,"activeCount":100},[],{"trials":792,"activeCount":100},[],{"trials":794,"activeCount":100},[],{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":96,"soonestReadout":66},[799],{"nctId":64,"briefTitle":65,"status":110,"phases":800,"primaryCompletion":66,"completion":801,"start":802,"enrollment":781,"conditions":803,"interventions":805},[93],"2026-12-31","2017-12-22",[804],"Osteoarthritis Post-meniscectomy",[67],{"intervention":807,"totalTrials":453,"cells":808},"Metformin",{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":837,"PHASE4":839,"NA":850},{"trials":810,"activeCount":100},[],{"trials":812,"activeCount":100},[],{"trials":814,"activeCount":100},[815,824],{"nctId":816,"briefTitle":817,"status":308,"phases":818,"primaryCompletion":819,"completion":819,"start":820,"enrollment":419,"conditions":821,"interventions":823},"NCT02815397","DA-EPOCH-Rituximab\u002FMetformin (RM) for Double Hit Lymphoma",[90],"2016-07","2016-02",[822],"Diffuse Large B-Cell Lymphoma",[807],{"nctId":825,"briefTitle":826,"status":308,"phases":827,"primaryCompletion":819,"completion":819,"start":828,"enrollment":34,"conditions":829,"interventions":830},"NCT02531308","Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)",[90],"2015-07",[822],[807,831,832,833,834,835,836],"Rituximab","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone","pegfilgrastim",{"trials":838,"activeCount":100},[],{"trials":840,"activeCount":100},[841],{"nctId":842,"briefTitle":843,"status":276,"phases":844,"primaryCompletion":845,"completion":845,"start":846,"enrollment":402,"conditions":847,"interventions":849},"NCT00682448","Metformin for the Prevention of the Metabolic Side-effects of Zyprexa",[92],"2011-08","2007-08",[848],"Metabolic Complications",[807],{"trials":851,"activeCount":100},[],{"intervention":853,"totalTrials":419,"cells":854},"Amantadine",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":872,"PHASE4":874,"NA":887},{"trials":856,"activeCount":100},[],{"trials":858,"activeCount":100},[],{"trials":860,"activeCount":100},[861],{"nctId":862,"briefTitle":863,"status":308,"phases":864,"primaryCompletion":819,"completion":819,"start":865,"enrollment":866,"conditions":867,"interventions":870},"NCT01789047","Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease",[90],"2013-03",42,[868,869],"Idiopathic Parkinson's Disease","Drug Induced Dyskinesia",[871,853],"Topiramate",{"trials":873,"activeCount":100},[],{"trials":875,"activeCount":100},[876],{"nctId":877,"briefTitle":878,"status":276,"phases":879,"primaryCompletion":880,"completion":881,"start":882,"enrollment":883,"conditions":884,"interventions":886},"NCT01071395","Validation of Dyskinesia Rating Scales",[92],"2012-04","2013-06","2010-01",68,[885],"Parkinson's Disease",[853],{"trials":888,"activeCount":100},[],{"intervention":890,"totalTrials":419,"cells":891},"Aminophylline",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":898,"PHASE4":900,"NA":922},{"trials":893,"activeCount":100},[],{"trials":895,"activeCount":100},[],{"trials":897,"activeCount":100},[],{"trials":899,"activeCount":100},[],{"trials":901,"activeCount":100},[902,912],{"nctId":903,"briefTitle":904,"status":276,"phases":905,"primaryCompletion":906,"completion":906,"start":907,"enrollment":908,"conditions":909,"interventions":911},"NCT01336140","Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging",[92],"2012-05","2011-06",300,[910],"Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson",[890],{"nctId":913,"briefTitle":914,"status":308,"phases":915,"primaryCompletion":916,"completion":916,"start":917,"enrollment":918,"conditions":919,"interventions":921},"NCT01250496","Study With Aminophylline to Attenuate of the Side Effects of Regadenoson",[92],"2011-11","2010-11",248,[920],"Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan",[890],{"trials":923,"activeCount":100},[],{"intervention":925,"totalTrials":96,"cells":926},"Vitamin D",{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":935,"NA":947},{"trials":928,"activeCount":100},[],{"trials":930,"activeCount":100},[],{"trials":932,"activeCount":100},[],{"trials":934,"activeCount":100},[],{"trials":936,"activeCount":100},[937],{"nctId":938,"briefTitle":939,"status":276,"phases":940,"primaryCompletion":941,"completion":301,"start":942,"enrollment":943,"conditions":944,"interventions":945},"NCT04177758","Evaluating Vitamin D3 Supplement on Post-Op Outcomes",[92],"2021-10-08","2020-02-01",137,[33],[925,946],"Control",{"trials":948,"activeCount":100},[],{"intervention":946,"totalTrials":96,"cells":950},{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":965},{"trials":952,"activeCount":100},[],{"trials":954,"activeCount":100},[],{"trials":956,"activeCount":100},[],{"trials":958,"activeCount":100},[],{"trials":960,"activeCount":100},[961],{"nctId":938,"briefTitle":939,"status":276,"phases":962,"primaryCompletion":941,"completion":301,"start":942,"enrollment":943,"conditions":963,"interventions":964},[92],[33],[925,946],{"trials":966,"activeCount":100},[],{"intervention":968,"totalTrials":96,"cells":969},"Eszopiclone",{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":990},{"trials":971,"activeCount":100},[],{"trials":973,"activeCount":100},[],{"trials":975,"activeCount":100},[],{"trials":977,"activeCount":100},[],{"trials":979,"activeCount":100},[980],{"nctId":981,"briefTitle":982,"status":276,"phases":983,"primaryCompletion":984,"completion":984,"start":985,"enrollment":986,"conditions":987,"interventions":989},"NCT01605253","Eszopiclone for the Treatment of Posttraumatic Stress Disorder",[92],"2015-12","2012-03",81,[988],"Posttraumatic Stress Disorders",[968],{"trials":991,"activeCount":100},[],{"intervention":993,"totalTrials":96,"cells":994},"mixed salts amphetamine",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1015},{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":100},[],{"trials":1000,"activeCount":100},[],{"trials":1002,"activeCount":100},[],{"trials":1004,"activeCount":100},[1005],{"nctId":1006,"briefTitle":1007,"status":276,"phases":1008,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1014},"NCT02058693","Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy",[92],"2014-12","2010-12",41,[1013],"Major Depressive Disorder",[993],{"trials":1016,"activeCount":100},[],{"intervention":1018,"totalTrials":96,"cells":1019},"Duloxetine",{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1026,"PHASE4":1028,"NA":1042},{"trials":1021,"activeCount":100},[],{"trials":1023,"activeCount":100},[],{"trials":1025,"activeCount":100},[],{"trials":1027,"activeCount":100},[],{"trials":1029,"activeCount":100},[1030],{"nctId":1031,"briefTitle":1032,"status":276,"phases":1033,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":1038,"interventions":1040},"NCT05086393","Duloxetine RCT on Postop TKA Outcomes",[92],"2025-06-01","2025-07-23","2021-11-01",241,[1039,24],"Pain, Postoperative",[1018,1041],"Placebos",{"trials":1043,"activeCount":100},[],{"intervention":1041,"totalTrials":96,"cells":1045},{"EARLY_PHASE1":1046,"PHASE1":1048,"PHASE2":1050,"PHASE3":1052,"PHASE4":1054,"NA":1060},{"trials":1047,"activeCount":100},[],{"trials":1049,"activeCount":100},[],{"trials":1051,"activeCount":100},[],{"trials":1053,"activeCount":100},[],{"trials":1055,"activeCount":100},[1056],{"nctId":1031,"briefTitle":1032,"status":276,"phases":1057,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":1058,"interventions":1059},[92],[1039,24],[1018,1041],{"trials":1061,"activeCount":100},[],{"intervention":1063,"totalTrials":96,"cells":1064},"Lopinavir 400 mg\u002Fritonavir 100 mg",{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1071,"PHASE4":1073,"NA":1085},{"trials":1066,"activeCount":100},[],{"trials":1068,"activeCount":100},[],{"trials":1070,"activeCount":100},[],{"trials":1072,"activeCount":100},[],{"trials":1074,"activeCount":100},[1075],{"nctId":1076,"briefTitle":1077,"status":308,"phases":1078,"primaryCompletion":1010,"completion":1079,"start":1080,"enrollment":9,"conditions":1081,"interventions":1083},"NCT00775606","Immune Reconstitution of Lopinavir\u002FRitonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease",[92],"2011-01","2008-10",[1082],"Acquired Immune Deficiency Syndrome",[1063,1084],"Efavirenz",{"trials":1086,"activeCount":100},[],{"intervention":1084,"totalTrials":96,"cells":1088},{"EARLY_PHASE1":1089,"PHASE1":1091,"PHASE2":1093,"PHASE3":1095,"PHASE4":1097,"NA":1103},{"trials":1090,"activeCount":100},[],{"trials":1092,"activeCount":100},[],{"trials":1094,"activeCount":100},[],{"trials":1096,"activeCount":100},[],{"trials":1098,"activeCount":100},[1099],{"nctId":1076,"briefTitle":1077,"status":308,"phases":1100,"primaryCompletion":1010,"completion":1079,"start":1080,"enrollment":9,"conditions":1101,"interventions":1102},[92],[1082],[1063,1084],{"trials":1104,"activeCount":100},[],{"intervention":1106,"totalTrials":96,"cells":1107},"Furosemide",{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1114,"PHASE4":1116,"NA":1132},{"trials":1109,"activeCount":100},[],{"trials":1111,"activeCount":100},[],{"trials":1113,"activeCount":100},[],{"trials":1115,"activeCount":100},[],{"trials":1117,"activeCount":100},[1118],{"nctId":1119,"briefTitle":1120,"status":308,"phases":1121,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":1125,"conditions":1126,"interventions":1130},"NCT04216784","Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients",[92],"2023-12-30","2024-04-01","2019-12-19",21,[1127,1128,1129],"Cirrhosis, Liver","Volume Overload","Fluid Overload",[1106,1131],"Albumin Human",{"trials":1133,"activeCount":100},[],{"intervention":1131,"totalTrials":96,"cells":1135},{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1142,"PHASE4":1144,"NA":1150},{"trials":1137,"activeCount":100},[],{"trials":1139,"activeCount":100},[],{"trials":1141,"activeCount":100},[],{"trials":1143,"activeCount":100},[],{"trials":1145,"activeCount":100},[1146],{"nctId":1119,"briefTitle":1120,"status":308,"phases":1147,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":1125,"conditions":1148,"interventions":1149},[92],[1127,1128,1129],[1106,1131],{"trials":1151,"activeCount":100},[],{"intervention":1153,"totalTrials":96,"cells":1154},"comparing 2 drugs on their effect on the bowel preparation for colonoscopy",{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1161,"PHASE4":1163,"NA":1176},{"trials":1156,"activeCount":100},[],{"trials":1158,"activeCount":100},[],{"trials":1160,"activeCount":100},[],{"trials":1162,"activeCount":100},[],{"trials":1164,"activeCount":100},[1165],{"nctId":1166,"briefTitle":1167,"status":276,"phases":1168,"primaryCompletion":1169,"completion":1170,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1175},"NCT01695863","Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep",[92],"2012-11","2014-01","2012-02",150,[1174],"Colorectal Cancer",[1153],{"trials":1177,"activeCount":100},[],{"intervention":1179,"totalTrials":96,"cells":1180},"Pregabalin-Lyrica",{"EARLY_PHASE1":1181,"PHASE1":1183,"PHASE2":1185,"PHASE3":1187,"PHASE4":1189,"NA":1202},{"trials":1182,"activeCount":100},[],{"trials":1184,"activeCount":100},[],{"trials":1186,"activeCount":100},[],{"trials":1188,"activeCount":100},[],{"trials":1190,"activeCount":100},[1191],{"nctId":1192,"briefTitle":1193,"status":259,"phases":1194,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":100,"conditions":1197,"interventions":1200},"NCT01309074","Does Pregabalin Improve Symptoms of Anxiety in Patients With Epilepsy? A Comparison With Sertraline",[92],"2012-12","2009-11",[1198,1199],"Epilepsy","Anxiety",[1179,1201],"Sertraline",{"trials":1203,"activeCount":100},[],{"intervention":1201,"totalTrials":96,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1212,"PHASE4":1214,"NA":1220},{"trials":1207,"activeCount":100},[],{"trials":1209,"activeCount":100},[],{"trials":1211,"activeCount":100},[],{"trials":1213,"activeCount":100},[],{"trials":1215,"activeCount":100},[1216],{"nctId":1192,"briefTitle":1193,"status":259,"phases":1217,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":100,"conditions":1218,"interventions":1219},[92],[1198,1199],[1179,1201],{"trials":1221,"activeCount":100},[],{"intervention":1223,"totalTrials":96,"cells":1224},"LMX 4 Topical Cream",{"EARLY_PHASE1":1225,"PHASE1":1227,"PHASE2":1229,"PHASE3":1231,"PHASE4":1233,"NA":1245},{"trials":1226,"activeCount":100},[],{"trials":1228,"activeCount":100},[],{"trials":1230,"activeCount":100},[],{"trials":1232,"activeCount":100},[],{"trials":1234,"activeCount":100},[1235],{"nctId":1236,"briefTitle":1237,"status":259,"phases":1238,"primaryCompletion":1239,"completion":1240,"start":1241,"enrollment":100,"conditions":1242,"interventions":1244},"NCT05461053","Conservative Management of Cutaneous Abscess",[92],"2026-01","2027-01","2025-01",[1243],"Cutaneous Abscess",[1223],{"trials":1246,"activeCount":100},[],{"intervention":1248,"totalTrials":96,"cells":1249},"Folic Acid",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1272},{"trials":1251,"activeCount":100},[],{"trials":1253,"activeCount":100},[],{"trials":1255,"activeCount":100},[],{"trials":1257,"activeCount":100},[],{"trials":1259,"activeCount":100},[1260],{"nctId":1261,"briefTitle":1262,"status":276,"phases":1263,"primaryCompletion":1264,"completion":1264,"start":1265,"enrollment":1266,"conditions":1267,"interventions":1271},"NCT04024254","A Study of Serum Folate Levels in Patients Treated With Olaparib",[92],"2025-12-31","2020-07-21",10,[1268,1269,1270],"Ovarian Cancer","Breast Cancer","Folic Acid Deficiency",[1248],{"trials":1273,"activeCount":100},[],{"intervention":1275,"totalTrials":96,"cells":1276},"insulin regular IV",{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1283,"PHASE4":1285,"NA":1298},{"trials":1278,"activeCount":100},[],{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":100},[],{"trials":1286,"activeCount":100},[1287],{"nctId":1288,"briefTitle":1289,"status":276,"phases":1290,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":1293,"conditions":1294,"interventions":1296},"NCT00795015","Comparison of the Leuven Protocol With the Glucommander for Postoperative Control of Blood Glucose With IV Insulin",[92],"2006-12","2006-04",93,[1295],"Diabetes",[1275,1297],"IV insulin",{"trials":1299,"activeCount":100},[],{"intervention":1297,"totalTrials":96,"cells":1301},{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1308,"PHASE4":1310,"NA":1316},{"trials":1303,"activeCount":100},[],{"trials":1305,"activeCount":100},[],{"trials":1307,"activeCount":100},[],{"trials":1309,"activeCount":100},[],{"trials":1311,"activeCount":100},[1312],{"nctId":1288,"briefTitle":1289,"status":276,"phases":1313,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":1293,"conditions":1314,"interventions":1315},[92],[1295],[1275,1297],{"trials":1317,"activeCount":100},[],{"intervention":1319,"totalTrials":96,"cells":1320},"metformin and sitagliptin",{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1325,"PHASE3":1327,"PHASE4":1329,"NA":1341},{"trials":1322,"activeCount":100},[],{"trials":1324,"activeCount":100},[],{"trials":1326,"activeCount":100},[],{"trials":1328,"activeCount":100},[],{"trials":1330,"activeCount":100},[1331],{"nctId":1332,"briefTitle":1333,"status":259,"phases":1334,"primaryCompletion":1335,"completion":1335,"start":1336,"enrollment":100,"conditions":1337,"interventions":1339},"NCT02250794","Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit",[92],"2015-05","2014-10",[1338],"Type 2 Diabetes Mellitus",[1319,1340,1319,1340],"insulin glargine and insulin lispro",{"trials":1342,"activeCount":100},[],{"intervention":1340,"totalTrials":96,"cells":1344},{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1349,"PHASE3":1351,"PHASE4":1353,"NA":1359},{"trials":1346,"activeCount":100},[],{"trials":1348,"activeCount":100},[],{"trials":1350,"activeCount":100},[],{"trials":1352,"activeCount":100},[],{"trials":1354,"activeCount":100},[1355],{"nctId":1332,"briefTitle":1333,"status":259,"phases":1356,"primaryCompletion":1335,"completion":1335,"start":1336,"enrollment":100,"conditions":1357,"interventions":1358},[92],[1338],[1319,1340,1319,1340],{"trials":1360,"activeCount":100},[],{"intervention":1362,"totalTrials":96,"cells":1363},"Fluticasone furoate nasal spray",{"EARLY_PHASE1":1364,"PHASE1":1366,"PHASE2":1368,"PHASE3":1370,"PHASE4":1372,"NA":1385},{"trials":1365,"activeCount":100},[],{"trials":1367,"activeCount":100},[],{"trials":1369,"activeCount":100},[],{"trials":1371,"activeCount":100},[],{"trials":1373,"activeCount":100},[1374],{"nctId":1375,"briefTitle":1376,"status":276,"phases":1377,"primaryCompletion":1378,"completion":1379,"start":1380,"enrollment":1381,"conditions":1382,"interventions":1384},"NCT00891436","Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms",[92],"2009-07","2009-08","2009-04",20,[1383],"Allergic Conjunctivitis to Tree Pollen or Grass Pollen",[1362],{"trials":1386,"activeCount":100},[],{"intervention":1388,"totalTrials":96,"cells":1389},"insulin aspart",{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1396,"PHASE4":1398,"NA":1409},{"trials":1391,"activeCount":100},[],{"trials":1393,"activeCount":100},[],{"trials":1395,"activeCount":100},[],{"trials":1397,"activeCount":100},[],{"trials":1399,"activeCount":100},[1400],{"nctId":1401,"briefTitle":1402,"status":276,"phases":1403,"primaryCompletion":1378,"completion":1378,"start":1404,"enrollment":1405,"conditions":1406,"interventions":1407},"NCT00591227","Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.",[92],"2008-05",176,[1338],[1388,1408],"insulin detemir",{"trials":1410,"activeCount":100},[],{"intervention":1408,"totalTrials":96,"cells":1412},{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1419,"PHASE4":1421,"NA":1427},{"trials":1414,"activeCount":100},[],{"trials":1416,"activeCount":100},[],{"trials":1418,"activeCount":100},[],{"trials":1420,"activeCount":100},[],{"trials":1422,"activeCount":100},[1423],{"nctId":1401,"briefTitle":1402,"status":276,"phases":1424,"primaryCompletion":1378,"completion":1378,"start":1404,"enrollment":1405,"conditions":1425,"interventions":1426},[92],[1338],[1388,1408],{"trials":1428,"activeCount":100},[],{"intervention":1430,"totalTrials":96,"cells":1431},"aspart",{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1436,"PHASE3":1438,"PHASE4":1440,"NA":1451},{"trials":1433,"activeCount":100},[],{"trials":1435,"activeCount":100},[],{"trials":1437,"activeCount":100},[],{"trials":1439,"activeCount":100},[],{"trials":1441,"activeCount":100},[1442],{"nctId":1443,"briefTitle":1444,"status":308,"phases":1445,"primaryCompletion":1195,"completion":1195,"start":1446,"enrollment":1447,"conditions":1448,"interventions":1449},"NCT01333514","Carbohydrate Consumption as a Factor in Aspart Dosing",[92],"2011-04",14,[1295],[1430,1450],"aspart- Insulin",{"trials":1452,"activeCount":100},[],{"intervention":1450,"totalTrials":96,"cells":1454},{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1461,"PHASE4":1463,"NA":1469},{"trials":1456,"activeCount":100},[],{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[],{"trials":1462,"activeCount":100},[],{"trials":1464,"activeCount":100},[1465],{"nctId":1443,"briefTitle":1444,"status":308,"phases":1466,"primaryCompletion":1195,"completion":1195,"start":1446,"enrollment":1447,"conditions":1467,"interventions":1468},[92],[1295],[1430,1450],{"trials":1470,"activeCount":100},[],{"intervention":1472,"totalTrials":96,"cells":1473},"Dexamethasone 4mg",{"EARLY_PHASE1":1474,"PHASE1":1476,"PHASE2":1478,"PHASE3":1480,"PHASE4":1482,"NA":1496},{"trials":1475,"activeCount":100},[],{"trials":1477,"activeCount":100},[],{"trials":1479,"activeCount":100},[],{"trials":1481,"activeCount":100},[],{"trials":1483,"activeCount":100},[1484],{"nctId":1485,"briefTitle":1486,"status":276,"phases":1487,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":1492,"interventions":1493},"NCT05018091","Dexamethasone in Total Knee Arthroplasty",[92],"2025-01-01","2025-05-30","2021-10-28",404,[24],[1472,1494,1495],"Dexamethasone 8 Mg\u002FmL Injectable Suspension","Dexamethasone 16mg",{"trials":1497,"activeCount":100},[],{"intervention":1494,"totalTrials":96,"cells":1499},{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1514},{"trials":1501,"activeCount":100},[],{"trials":1503,"activeCount":100},[],{"trials":1505,"activeCount":100},[],{"trials":1507,"activeCount":100},[],{"trials":1509,"activeCount":100},[1510],{"nctId":1485,"briefTitle":1486,"status":276,"phases":1511,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":1512,"interventions":1513},[92],[24],[1472,1494,1495],{"trials":1515,"activeCount":100},[],{"intervention":1495,"totalTrials":96,"cells":1517},{"EARLY_PHASE1":1518,"PHASE1":1520,"PHASE2":1522,"PHASE3":1524,"PHASE4":1526,"NA":1532},{"trials":1519,"activeCount":100},[],{"trials":1521,"activeCount":100},[],{"trials":1523,"activeCount":100},[],{"trials":1525,"activeCount":100},[],{"trials":1527,"activeCount":100},[1528],{"nctId":1485,"briefTitle":1486,"status":276,"phases":1529,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":1530,"interventions":1531},[92],[24],[1472,1494,1495],{"trials":1533,"activeCount":100},[],{"intervention":1535,"totalTrials":96,"cells":1536},"Alefacept",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1545,"NA":1556},{"trials":1538,"activeCount":100},[],{"trials":1540,"activeCount":100},[],{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[1547],{"nctId":1548,"briefTitle":1549,"status":276,"phases":1550,"primaryCompletion":1551,"completion":1552,"start":112,"enrollment":34,"conditions":1553,"interventions":1555},"NCT00832585","Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis",[92],"2009-09","2009-10",[1554],"Atopic Dermatitis",[1535],{"trials":1557,"activeCount":100},[],{"intervention":1559,"totalTrials":96,"cells":1560},"Evening Group",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1567,"PHASE4":1569,"NA":1583},{"trials":1562,"activeCount":100},[],{"trials":1564,"activeCount":100},[],{"trials":1566,"activeCount":100},[],{"trials":1568,"activeCount":100},[],{"trials":1570,"activeCount":100},[1571],{"nctId":1572,"briefTitle":1573,"status":276,"phases":1574,"primaryCompletion":1575,"completion":1576,"start":1577,"enrollment":1578,"conditions":1579,"interventions":1581},"NCT04304950","Chronotherapy in Inflammatory Bowel Disease",[92],"2021-12","2023-04","2016-04-25",28,[1580],"Inflammatory Bowel Diseases",[1559,1582],"Morning Group",{"trials":1584,"activeCount":100},[],{"intervention":1582,"totalTrials":96,"cells":1586},{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1593,"PHASE4":1595,"NA":1601},{"trials":1588,"activeCount":100},[],{"trials":1590,"activeCount":100},[],{"trials":1592,"activeCount":100},[],{"trials":1594,"activeCount":100},[],{"trials":1596,"activeCount":100},[1597],{"nctId":1572,"briefTitle":1573,"status":276,"phases":1598,"primaryCompletion":1575,"completion":1576,"start":1577,"enrollment":1578,"conditions":1599,"interventions":1600},[92],[1580],[1559,1582],{"trials":1602,"activeCount":100},[],{"intervention":1604,"totalTrials":96,"cells":1605},"opioid pain pills",{"EARLY_PHASE1":1606,"PHASE1":1608,"PHASE2":1610,"PHASE3":1612,"PHASE4":1614,"NA":1627},{"trials":1607,"activeCount":100},[],{"trials":1609,"activeCount":100},[],{"trials":1611,"activeCount":100},[],{"trials":1613,"activeCount":100},[],{"trials":1615,"activeCount":100},[1616],{"nctId":1617,"briefTitle":1618,"status":276,"phases":1619,"primaryCompletion":1620,"completion":1621,"start":1622,"enrollment":1623,"conditions":1624,"interventions":1626},"NCT03236155","Comparing Opioid Prescription Patterns in Total Joint Arthroplasty Patients",[92],"2018-07-01","2018-08-26","2017-07-01",304,[1625],"Postoperative Pain",[1604],{"trials":1628,"activeCount":100},[],{"intervention":1630,"totalTrials":96,"cells":1631},"vortioxetine",{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1638,"PHASE4":1640,"NA":1651},{"trials":1633,"activeCount":100},[],{"trials":1635,"activeCount":100},[],{"trials":1637,"activeCount":100},[],{"trials":1639,"activeCount":100},[],{"trials":1641,"activeCount":100},[1642],{"nctId":1643,"briefTitle":1644,"status":276,"phases":1645,"primaryCompletion":1646,"completion":1646,"start":1647,"enrollment":1648,"conditions":1649,"interventions":1650},"NCT02749721","The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder",[92],"2019-01-31","2016-12",31,[1013],[1630],{"trials":1652,"activeCount":100},[],{"intervention":500,"totalTrials":96,"cells":1654},{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1659,"PHASE3":1661,"PHASE4":1663,"NA":1669},{"trials":1656,"activeCount":100},[],{"trials":1658,"activeCount":100},[],{"trials":1660,"activeCount":100},[],{"trials":1662,"activeCount":100},[],{"trials":1664,"activeCount":100},[1665],{"nctId":492,"briefTitle":493,"status":259,"phases":1666,"primaryCompletion":495,"completion":495,"start":496,"enrollment":100,"conditions":1667,"interventions":1668},[92],[15,498],[500,501,480,86,502],{"trials":1670,"activeCount":100},[],{"intervention":501,"totalTrials":96,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1687},{"trials":1674,"activeCount":100},[],{"trials":1676,"activeCount":100},[],{"trials":1678,"activeCount":100},[],{"trials":1680,"activeCount":100},[],{"trials":1682,"activeCount":100},[1683],{"nctId":492,"briefTitle":493,"status":259,"phases":1684,"primaryCompletion":495,"completion":495,"start":496,"enrollment":100,"conditions":1685,"interventions":1686},[92],[15,498],[500,501,480,86,502],{"trials":1688,"activeCount":100},[],{"intervention":502,"totalTrials":96,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1697,"PHASE4":1699,"NA":1705},{"trials":1692,"activeCount":100},[],{"trials":1694,"activeCount":100},[],{"trials":1696,"activeCount":100},[],{"trials":1698,"activeCount":100},[],{"trials":1700,"activeCount":100},[1701],{"nctId":492,"briefTitle":493,"status":259,"phases":1702,"primaryCompletion":495,"completion":495,"start":496,"enrollment":100,"conditions":1703,"interventions":1704},[92],[15,498],[500,501,480,86,502],{"trials":1706,"activeCount":100},[],{"intervention":1708,"totalTrials":96,"cells":1709},"ASSUAGE Protocol",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1716,"PHASE4":1718,"NA":1729},{"trials":1711,"activeCount":100},[],{"trials":1713,"activeCount":100},[],{"trials":1715,"activeCount":100},[],{"trials":1717,"activeCount":100},[],{"trials":1719,"activeCount":100},[1720],{"nctId":1721,"briefTitle":1722,"status":259,"phases":1723,"primaryCompletion":1724,"completion":1724,"start":1725,"enrollment":100,"conditions":1726,"interventions":1728},"NCT01655524","The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion",[92],"2014-07","2012-07",[1727],"Coronary Artery Disease",[1708],{"trials":1730,"activeCount":100},[],{"intervention":1732,"totalTrials":96,"cells":1733},"Conventional Oral TXA",{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1740,"PHASE4":1742,"NA":1756},{"trials":1735,"activeCount":100},[],{"trials":1737,"activeCount":100},[],{"trials":1739,"activeCount":100},[],{"trials":1741,"activeCount":100},[],{"trials":1743,"activeCount":100},[1744],{"nctId":1745,"briefTitle":1746,"status":259,"phases":1747,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":100,"conditions":1750,"interventions":1754},"NCT02926651","Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty",[92],"2017-07","2016-10",[1751,1752,24,1753],"Anemia","Arthritis","Total Hip Arthroplasty",[1732,1755],"Multi-Dose Oral TXA",{"trials":1757,"activeCount":100},[],{"intervention":1755,"totalTrials":96,"cells":1759},{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1766,"PHASE4":1768,"NA":1774},{"trials":1761,"activeCount":100},[],{"trials":1763,"activeCount":100},[],{"trials":1765,"activeCount":100},[],{"trials":1767,"activeCount":100},[],{"trials":1769,"activeCount":100},[1770],{"nctId":1745,"briefTitle":1746,"status":259,"phases":1771,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":100,"conditions":1772,"interventions":1773},[92],[1751,1752,24,1753],[1732,1755],{"trials":1775,"activeCount":100},[],{"intervention":284,"totalTrials":419,"cells":1777},{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1784,"PHASE4":1794,"NA":1796},{"trials":1779,"activeCount":100},[],{"trials":1781,"activeCount":100},[],{"trials":1783,"activeCount":100},[],{"trials":1785,"activeCount":100},[1786,1790],{"nctId":274,"briefTitle":275,"status":276,"phases":1787,"primaryCompletion":278,"completion":278,"start":279,"enrollment":280,"conditions":1788,"interventions":1789},[91],[282],[52,284],{"nctId":286,"briefTitle":287,"status":276,"phases":1791,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":1792,"interventions":1793},[91],[294],[52,284],{"trials":1795,"activeCount":100},[],{"trials":1797,"activeCount":100},[],{"intervention":1799,"totalTrials":96,"cells":1800},"Evicel Fibrin Spray",{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1807,"PHASE4":1818,"NA":1820},{"trials":1802,"activeCount":100},[],{"trials":1804,"activeCount":100},[],{"trials":1806,"activeCount":100},[],{"trials":1808,"activeCount":100},[1809],{"nctId":1810,"briefTitle":1811,"status":276,"phases":1812,"primaryCompletion":1009,"completion":1813,"start":906,"enrollment":1814,"conditions":1815,"interventions":1817},"NCT01656759","Use of a Novel Fibrin Sealant in Total Knee Arthroplasty",[90,91],"2015-08",73,[15,1816],"Intraoperative Bleeding",[1799],{"trials":1819,"activeCount":100},[],{"trials":1821,"activeCount":100},[],{"intervention":1823,"totalTrials":96,"cells":1824},"risperidone",{"EARLY_PHASE1":1825,"PHASE1":1827,"PHASE2":1829,"PHASE3":1831,"PHASE4":1842,"NA":1844},{"trials":1826,"activeCount":100},[],{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[1833],{"nctId":1834,"briefTitle":1835,"status":308,"phases":1836,"completion":846,"start":1837,"enrollment":1838,"conditions":1839,"interventions":1841},"NCT00174590","Treatment of Major Depressive Disorder With Psychotic Features.",[91],"2001-09",30,[1840],"Major Depression With Psychotic Features",[1823],{"trials":1843,"activeCount":100},[],{"trials":1845,"activeCount":100},[],{"intervention":1847,"totalTrials":96,"cells":1848},"TDF\u002FFTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily",{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1855,"PHASE4":1866,"NA":1868},{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[],{"trials":1854,"activeCount":100},[],{"trials":1856,"activeCount":100},[1857],{"nctId":1858,"briefTitle":1859,"status":259,"phases":1860,"primaryCompletion":881,"completion":1861,"start":907,"enrollment":100,"conditions":1862,"interventions":1864},"NCT00984152","Trial of TDF\u002FFTC + Raltegravir Versus TDF\u002FFTC + Efavirenz in HIV-1-Infected Women",[91],"2013-12",[1863],"HIV-1 Infections",[1847,1865],"TDF\u002FFTC + Efavirenz (Atripla) Once-Daily",{"trials":1867,"activeCount":100},[],{"trials":1869,"activeCount":100},[],{"intervention":1865,"totalTrials":96,"cells":1871},{"EARLY_PHASE1":1872,"PHASE1":1874,"PHASE2":1876,"PHASE3":1878,"PHASE4":1884,"NA":1886},{"trials":1873,"activeCount":100},[],{"trials":1875,"activeCount":100},[],{"trials":1877,"activeCount":100},[],{"trials":1879,"activeCount":100},[1880],{"nctId":1858,"briefTitle":1859,"status":259,"phases":1881,"primaryCompletion":881,"completion":1861,"start":907,"enrollment":100,"conditions":1882,"interventions":1883},[91],[1863],[1847,1865],{"trials":1885,"activeCount":100},[],{"trials":1887,"activeCount":100},[],{"intervention":477,"totalTrials":96,"cells":1889},{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1896,"PHASE4":1902,"NA":1904},{"trials":1891,"activeCount":100},[],{"trials":1893,"activeCount":100},[],{"trials":1895,"activeCount":100},[],{"trials":1897,"activeCount":100},[1898],{"nctId":468,"briefTitle":469,"status":259,"phases":1899,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":1900,"interventions":1901},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":1903,"activeCount":100},[],{"trials":1905,"activeCount":100},[],{"intervention":478,"totalTrials":96,"cells":1907},{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1914,"PHASE4":1920,"NA":1922},{"trials":1909,"activeCount":100},[],{"trials":1911,"activeCount":100},[],{"trials":1913,"activeCount":100},[],{"trials":1915,"activeCount":100},[1916],{"nctId":468,"briefTitle":469,"status":259,"phases":1917,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":1918,"interventions":1919},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":1921,"activeCount":100},[],{"trials":1923,"activeCount":100},[],{"intervention":479,"totalTrials":96,"cells":1925},{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1932,"PHASE4":1938,"NA":1940},{"trials":1927,"activeCount":100},[],{"trials":1929,"activeCount":100},[],{"trials":1931,"activeCount":100},[],{"trials":1933,"activeCount":100},[1934],{"nctId":468,"briefTitle":469,"status":259,"phases":1935,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":1936,"interventions":1937},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":1939,"activeCount":100},[],{"trials":1941,"activeCount":100},[],{"intervention":481,"totalTrials":96,"cells":1943},{"EARLY_PHASE1":1944,"PHASE1":1946,"PHASE2":1948,"PHASE3":1950,"PHASE4":1956,"NA":1958},{"trials":1945,"activeCount":100},[],{"trials":1947,"activeCount":100},[],{"trials":1949,"activeCount":100},[],{"trials":1951,"activeCount":100},[1952],{"nctId":468,"briefTitle":469,"status":259,"phases":1953,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":1954,"interventions":1955},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":1957,"activeCount":100},[],{"trials":1959,"activeCount":100},[],{"intervention":482,"totalTrials":96,"cells":1961},{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1966,"PHASE3":1968,"PHASE4":1974,"NA":1976},{"trials":1963,"activeCount":100},[],{"trials":1965,"activeCount":100},[],{"trials":1967,"activeCount":100},[],{"trials":1969,"activeCount":100},[1970],{"nctId":468,"briefTitle":469,"status":259,"phases":1971,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":1972,"interventions":1973},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":1975,"activeCount":100},[],{"trials":1977,"activeCount":100},[],{"intervention":483,"totalTrials":96,"cells":1979},{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1984,"PHASE3":1986,"PHASE4":1992,"NA":1994},{"trials":1981,"activeCount":100},[],{"trials":1983,"activeCount":100},[],{"trials":1985,"activeCount":100},[],{"trials":1987,"activeCount":100},[1988],{"nctId":468,"briefTitle":469,"status":259,"phases":1989,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":1990,"interventions":1991},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":1993,"activeCount":100},[],{"trials":1995,"activeCount":100},[],{"intervention":484,"totalTrials":96,"cells":1997},{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2002,"PHASE3":2004,"PHASE4":2010,"NA":2012},{"trials":1999,"activeCount":100},[],{"trials":2001,"activeCount":100},[],{"trials":2003,"activeCount":100},[],{"trials":2005,"activeCount":100},[2006],{"nctId":468,"briefTitle":469,"status":259,"phases":2007,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":2008,"interventions":2009},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":2011,"activeCount":100},[],{"trials":2013,"activeCount":100},[],{"intervention":485,"totalTrials":96,"cells":2015},{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2020,"PHASE3":2022,"PHASE4":2028,"NA":2030},{"trials":2017,"activeCount":100},[],{"trials":2019,"activeCount":100},[],{"trials":2021,"activeCount":100},[],{"trials":2023,"activeCount":100},[2024],{"nctId":468,"briefTitle":469,"status":259,"phases":2025,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":2026,"interventions":2027},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":2029,"activeCount":100},[],{"trials":2031,"activeCount":100},[],{"intervention":486,"totalTrials":96,"cells":2033},{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2040,"PHASE4":2046,"NA":2048},{"trials":2035,"activeCount":100},[],{"trials":2037,"activeCount":100},[],{"trials":2039,"activeCount":100},[],{"trials":2041,"activeCount":100},[2042],{"nctId":468,"briefTitle":469,"status":259,"phases":2043,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":2044,"interventions":2045},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":2047,"activeCount":100},[],{"trials":2049,"activeCount":100},[],{"intervention":487,"totalTrials":96,"cells":2051},{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2058,"PHASE4":2064,"NA":2066},{"trials":2053,"activeCount":100},[],{"trials":2055,"activeCount":100},[],{"trials":2057,"activeCount":100},[],{"trials":2059,"activeCount":100},[2060],{"nctId":468,"briefTitle":469,"status":259,"phases":2061,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":2062,"interventions":2063},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":2065,"activeCount":100},[],{"trials":2067,"activeCount":100},[],{"intervention":488,"totalTrials":96,"cells":2069},{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2076,"PHASE4":2082,"NA":2084},{"trials":2071,"activeCount":100},[],{"trials":2073,"activeCount":100},[],{"trials":2075,"activeCount":100},[],{"trials":2077,"activeCount":100},[2078],{"nctId":468,"briefTitle":469,"status":259,"phases":2079,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":2080,"interventions":2081},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":2083,"activeCount":100},[],{"trials":2085,"activeCount":100},[],{"intervention":2087,"totalTrials":96,"cells":2088},"Tranexamic Acid standard dose",{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2095,"PHASE4":2108,"NA":2110},{"trials":2090,"activeCount":100},[],{"trials":2092,"activeCount":100},[],{"trials":2094,"activeCount":100},[],{"trials":2096,"activeCount":100},[2097],{"nctId":2098,"briefTitle":2099,"status":276,"phases":2100,"primaryCompletion":2101,"completion":2101,"start":906,"enrollment":2102,"conditions":2103,"interventions":2104},"NCT01651806","Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty",[90,91],"2015-03",65,[15,1816],[2087,2105,2106,2107],"Females Tranexamic Acid weighted dose","Females receiving a uniform dose of TA","Males Weighted Dose TA",{"trials":2109,"activeCount":100},[],{"trials":2111,"activeCount":100},[],{"intervention":2105,"totalTrials":96,"cells":2113},{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2120,"PHASE4":2126,"NA":2128},{"trials":2115,"activeCount":100},[],{"trials":2117,"activeCount":100},[],{"trials":2119,"activeCount":100},[],{"trials":2121,"activeCount":100},[2122],{"nctId":2098,"briefTitle":2099,"status":276,"phases":2123,"primaryCompletion":2101,"completion":2101,"start":906,"enrollment":2102,"conditions":2124,"interventions":2125},[90,91],[15,1816],[2087,2105,2106,2107],{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[],{"intervention":2106,"totalTrials":96,"cells":2131},{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2138,"PHASE4":2144,"NA":2146},{"trials":2133,"activeCount":100},[],{"trials":2135,"activeCount":100},[],{"trials":2137,"activeCount":100},[],{"trials":2139,"activeCount":100},[2140],{"nctId":2098,"briefTitle":2099,"status":276,"phases":2141,"primaryCompletion":2101,"completion":2101,"start":906,"enrollment":2102,"conditions":2142,"interventions":2143},[90,91],[15,1816],[2087,2105,2106,2107],{"trials":2145,"activeCount":100},[],{"trials":2147,"activeCount":100},[],{"intervention":2107,"totalTrials":96,"cells":2149},{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2154,"PHASE3":2156,"PHASE4":2162,"NA":2164},{"trials":2151,"activeCount":100},[],{"trials":2153,"activeCount":100},[],{"trials":2155,"activeCount":100},[],{"trials":2157,"activeCount":100},[2158],{"nctId":2098,"briefTitle":2099,"status":276,"phases":2159,"primaryCompletion":2101,"completion":2101,"start":906,"enrollment":2102,"conditions":2160,"interventions":2161},[90,91],[15,1816],[2087,2105,2106,2107],{"trials":2163,"activeCount":100},[],{"trials":2165,"activeCount":100},[],{"intervention":2167,"totalTrials":96,"cells":2168},"magnesium-cannabidiolic acid cream",{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2175,"PHASE4":2187,"NA":2189},{"trials":2170,"activeCount":100},[],{"trials":2172,"activeCount":100},[],{"trials":2174,"activeCount":100},[],{"trials":2176,"activeCount":100},[2177],{"nctId":2178,"briefTitle":2179,"status":308,"phases":2180,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":19,"conditions":2183,"interventions":2186},"NCT04103814","Effect of Topical CBD Cream for Degenerative Hallux Disorders",[90,91],"2023-05-15","2019-10-20",[2184,2185],"Hallux Valgus","Hallux Rigidus",[2167],{"trials":2188,"activeCount":100},[],{"trials":2190,"activeCount":100},[],{"intervention":2192,"totalTrials":96,"cells":2193},"o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1",{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2200,"PHASE4":2216,"NA":2218},{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[],{"trials":2199,"activeCount":100},[],{"trials":2201,"activeCount":100},[2202],{"nctId":2203,"briefTitle":2204,"status":276,"phases":2205,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":2209,"conditions":2210,"interventions":2213},"NCT02939287","Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan",[91],"2021-12-30","2022-12-01","2017-09-23",52,[2211,2212],"Nausea","Vomiting",[2192,2214,2215],"Olanzapine10 mg orally daily on Days -1,0,+1 and +2","Aprepitant plus Olanzapine",{"trials":2217,"activeCount":100},[],{"trials":2219,"activeCount":100},[],{"intervention":2214,"totalTrials":96,"cells":2221},{"EARLY_PHASE1":2222,"PHASE1":2224,"PHASE2":2226,"PHASE3":2228,"PHASE4":2234,"NA":2236},{"trials":2223,"activeCount":100},[],{"trials":2225,"activeCount":100},[],{"trials":2227,"activeCount":100},[],{"trials":2229,"activeCount":100},[2230],{"nctId":2203,"briefTitle":2204,"status":276,"phases":2231,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":2209,"conditions":2232,"interventions":2233},[91],[2211,2212],[2192,2214,2215],{"trials":2235,"activeCount":100},[],{"trials":2237,"activeCount":100},[],{"intervention":2215,"totalTrials":96,"cells":2239},{"EARLY_PHASE1":2240,"PHASE1":2242,"PHASE2":2244,"PHASE3":2246,"PHASE4":2252,"NA":2254},{"trials":2241,"activeCount":100},[],{"trials":2243,"activeCount":100},[],{"trials":2245,"activeCount":100},[],{"trials":2247,"activeCount":100},[2248],{"nctId":2203,"briefTitle":2204,"status":276,"phases":2249,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":2209,"conditions":2250,"interventions":2251},[91],[2211,2212],[2192,2214,2215],{"trials":2253,"activeCount":100},[],{"trials":2255,"activeCount":100},[],{"intervention":2257,"totalTrials":96,"cells":2258},"Alcohol",{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2265,"PHASE4":2281,"NA":2283},{"trials":2260,"activeCount":100},[],{"trials":2262,"activeCount":100},[],{"trials":2264,"activeCount":100},[],{"trials":2266,"activeCount":100},[2267],{"nctId":2268,"briefTitle":2269,"status":276,"phases":2270,"primaryCompletion":2271,"completion":2272,"start":2273,"enrollment":2274,"conditions":2275,"interventions":2280},"NCT00559819","Validation of Driving Simulator to Blood Alcohol Concentration Standards for Impaired Driving",[91],"2022-03","2022-07","2008-02",32,[2276,2277,2278,2279],"Driving","Intoxication","Impairment","Alcohol Impaired Driving",[2257],{"trials":2282,"activeCount":100},[],{"trials":2284,"activeCount":100},[],{"intervention":2286,"totalTrials":96,"cells":2287},"Dopamine",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2306,"NA":2308},{"trials":2289,"activeCount":100},[],{"trials":2291,"activeCount":100},[],{"trials":2293,"activeCount":100},[],{"trials":2295,"activeCount":100},[2296],{"nctId":2297,"briefTitle":2298,"status":276,"phases":2299,"primaryCompletion":1379,"completion":1379,"start":2300,"enrollment":2301,"conditions":2302,"interventions":2304},"NCT00604019","Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock",[91],"2003-03",252,[2303],"Septic Shock",[2286,2305],"Norepinephrine",{"trials":2307,"activeCount":100},[],{"trials":2309,"activeCount":100},[],{"intervention":2305,"totalTrials":96,"cells":2311},{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2318,"PHASE4":2324,"NA":2326},{"trials":2313,"activeCount":100},[],{"trials":2315,"activeCount":100},[],{"trials":2317,"activeCount":100},[],{"trials":2319,"activeCount":100},[2320],{"nctId":2297,"briefTitle":2298,"status":276,"phases":2321,"primaryCompletion":1379,"completion":1379,"start":2300,"enrollment":2301,"conditions":2322,"interventions":2323},[91],[2303],[2286,2305],{"trials":2325,"activeCount":100},[],{"trials":2327,"activeCount":100},[],{"intervention":2329,"totalTrials":96,"cells":2330},"quetiapine",{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2335,"PHASE3":2337,"PHASE4":2348,"NA":2350},{"trials":2332,"activeCount":100},[],{"trials":2334,"activeCount":100},[],{"trials":2336,"activeCount":100},[],{"trials":2338,"activeCount":100},[2339],{"nctId":2340,"briefTitle":2341,"status":308,"phases":2342,"completion":2343,"start":2344,"enrollment":2345,"conditions":2346,"interventions":2347},"NCT00174603","Treatment of Depression With Quetiapine",[91],"2007-01","2005-08",60,[1840],[2329],{"trials":2349,"activeCount":100},[],{"trials":2351,"activeCount":100},[],{"intervention":2353,"totalTrials":419,"cells":2354},"amifostine trihydrate",{"EARLY_PHASE1":2355,"PHASE1":2357,"PHASE2":2359,"PHASE3":2388,"PHASE4":2390,"NA":2392},{"trials":2356,"activeCount":100},[],{"trials":2358,"activeCount":100},[],{"trials":2360,"activeCount":100},[2361,2377],{"nctId":2362,"briefTitle":2363,"status":259,"phases":2364,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":100,"conditions":2367,"interventions":2369},"NCT00003405","Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia",[90],"1999-04","1998-04",[2368],"Leukemia",[2370,2353,2371,2372,2373,2374,2375,2376],"recombinant interferon alfa","bromodeoxyuridine","cytarabine","idarubicin","idoxuridine","isotretinoin","mitoxantrone hydrochloride",{"nctId":2378,"briefTitle":2379,"status":259,"phases":2380,"primaryCompletion":2381,"completion":2381,"start":2382,"enrollment":100,"conditions":2383,"interventions":2387},"NCT00003407","Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML",[90],"2004-04-07","2001-02-13",[2384,2368,2385,2386],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Myelodysplastic Syndromes","Neutropenia",[2353,2372,2376],{"trials":2389,"activeCount":100},[],{"trials":2391,"activeCount":100},[],{"trials":2393,"activeCount":100},[],{"intervention":2372,"totalTrials":419,"cells":2395},{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2400,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2397,"activeCount":100},[],{"trials":2399,"activeCount":100},[],{"trials":2401,"activeCount":100},[2402,2406],{"nctId":2362,"briefTitle":2363,"status":259,"phases":2403,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":100,"conditions":2404,"interventions":2405},[90],[2368],[2370,2353,2371,2372,2373,2374,2375,2376],{"nctId":2378,"briefTitle":2379,"status":259,"phases":2407,"primaryCompletion":2381,"completion":2381,"start":2382,"enrollment":100,"conditions":2408,"interventions":2409},[90],[2384,2368,2385,2386],[2353,2372,2376],{"trials":2411,"activeCount":100},[],{"trials":2413,"activeCount":100},[],{"trials":2415,"activeCount":100},[],{"intervention":2376,"totalTrials":419,"cells":2417},{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2422,"PHASE3":2432,"PHASE4":2434,"NA":2436},{"trials":2419,"activeCount":100},[],{"trials":2421,"activeCount":100},[],{"trials":2423,"activeCount":100},[2424,2428],{"nctId":2362,"briefTitle":2363,"status":259,"phases":2425,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":100,"conditions":2426,"interventions":2427},[90],[2368],[2370,2353,2371,2372,2373,2374,2375,2376],{"nctId":2378,"briefTitle":2379,"status":259,"phases":2429,"primaryCompletion":2381,"completion":2381,"start":2382,"enrollment":100,"conditions":2430,"interventions":2431},[90],[2384,2368,2385,2386],[2353,2372,2376],{"trials":2433,"activeCount":100},[],{"trials":2435,"activeCount":100},[],{"trials":2437,"activeCount":100},[],{"intervention":2439,"totalTrials":419,"cells":2440},"sugar pill",{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2445,"PHASE3":2467,"PHASE4":2469,"NA":2471},{"trials":2442,"activeCount":100},[],{"trials":2444,"activeCount":100},[],{"trials":2446,"activeCount":100},[2447,2456],{"nctId":2448,"briefTitle":2449,"status":259,"phases":2450,"enrollment":100,"conditions":2451,"interventions":2452},"NCT01351168","Use of Zolpidem in Parkinson's Disease",[90],[885],[2453,2454,2455,2439],"Levodopa","Zolpidem first dose","Zolpidem second dose",{"nctId":2457,"briefTitle":2458,"status":276,"phases":2459,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":2462,"conditions":2463,"interventions":2464},"NCT01341080","Varenicline for Gait and Balance Impairment in Parkinson Disease",[90],"2018-11-02","2010-12-28",40,[18],[2465,2466],"Varenicline","Sugar pill",{"trials":2468,"activeCount":100},[],{"trials":2470,"activeCount":100},[],{"trials":2472,"activeCount":100},[],{"intervention":2474,"totalTrials":96,"cells":2475},"Lenalidomide and azacitidine combination",{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2490,"PHASE4":2492,"NA":2494},{"trials":2477,"activeCount":100},[],{"trials":2479,"activeCount":100},[],{"trials":2481,"activeCount":100},[2482],{"nctId":2483,"briefTitle":2484,"status":308,"phases":2485,"primaryCompletion":2486,"completion":2486,"start":1079,"enrollment":419,"conditions":2487,"interventions":2489},"NCT01379274","A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes",[90],"2013-11",[2488],"MDS",[2474],{"trials":2491,"activeCount":100},[],{"trials":2493,"activeCount":100},[],{"trials":2495,"activeCount":100},[],{"intervention":2497,"totalTrials":96,"cells":2498},"Tissue Plasminogen Activator",{"EARLY_PHASE1":2499,"PHASE1":2501,"PHASE2":2503,"PHASE3":2516,"PHASE4":2518,"NA":2520},{"trials":2500,"activeCount":100},[],{"trials":2502,"activeCount":100},[],{"trials":2504,"activeCount":100},[2505],{"nctId":2506,"briefTitle":2507,"status":259,"phases":2508,"primaryCompletion":2509,"completion":2509,"start":2101,"enrollment":100,"conditions":2510,"interventions":2515},"NCT01878136","Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage",[89,90],"2016-09",[2511,2512,2513,2514],"Subarachnoid Hemorrhage","Cerebral Vasospasm","Cerebral Aneurysm","Hydrocephalus",[2497],{"trials":2517,"activeCount":100},[],{"trials":2519,"activeCount":100},[],{"trials":2521,"activeCount":100},[],{"intervention":2523,"totalTrials":96,"cells":2524},"Durvalumab",{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2526,"activeCount":100},[],{"trials":2528,"activeCount":100},[],{"trials":2530,"activeCount":100},[2531],{"nctId":2532,"briefTitle":2533,"status":308,"phases":2534,"primaryCompletion":2535,"completion":2535,"start":2536,"enrollment":1266,"conditions":2537,"interventions":2539},"NCT04441138","Chemoradiation Followed by Durvalumab in Poor Risk and\u002For Elderly Patients With Stage III NSCLC",[90],"2024-03-31","2021-02-25",[2538],"Stage III Non-small-cell Lung Cancer",[2523],{"trials":2541,"activeCount":100},[],{"trials":2543,"activeCount":100},[],{"trials":2545,"activeCount":100},[],{"intervention":2547,"totalTrials":96,"cells":2548},"Estradiol",{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2553,"PHASE3":2565,"PHASE4":2567,"NA":2569},{"trials":2550,"activeCount":100},[],{"trials":2552,"activeCount":100},[],{"trials":2554,"activeCount":100},[2555],{"nctId":2556,"briefTitle":2557,"status":259,"phases":2558,"primaryCompletion":2559,"completion":2559,"start":2560,"enrollment":100,"conditions":2561,"interventions":2564},"NCT01895881","Estrogen Therapy as Prevention in the Progression of Aneurysm (EPPA) Trial",[90],"2018-12","2013-04",[2513,2562,2563],"Menopause","Treatment",[2547],{"trials":2566,"activeCount":100},[],{"trials":2568,"activeCount":100},[],{"trials":2570,"activeCount":100},[],{"intervention":2572,"totalTrials":96,"cells":2573},"Oxytocin",{"EARLY_PHASE1":2574,"PHASE1":2576,"PHASE2":2578,"PHASE3":2589,"PHASE4":2591,"NA":2593},{"trials":2575,"activeCount":100},[],{"trials":2577,"activeCount":100},[],{"trials":2579,"activeCount":100},[2580],{"nctId":2581,"briefTitle":2582,"status":276,"phases":2583,"primaryCompletion":2584,"completion":2584,"start":2585,"enrollment":2462,"conditions":2586,"interventions":2588},"NCT02918864","Oxytocin and Social Cognitive Skills Groups",[90],"2021-09","2016-06-15",[2587],"Autism Spectrum Disorder",[2572],{"trials":2590,"activeCount":100},[],{"trials":2592,"activeCount":100},[],{"trials":2594,"activeCount":100},[],{"intervention":2370,"totalTrials":96,"cells":2596},{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2607,"PHASE4":2609,"NA":2611},{"trials":2598,"activeCount":100},[],{"trials":2600,"activeCount":100},[],{"trials":2602,"activeCount":100},[2603],{"nctId":2362,"briefTitle":2363,"status":259,"phases":2604,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":100,"conditions":2605,"interventions":2606},[90],[2368],[2370,2353,2371,2372,2373,2374,2375,2376],{"trials":2608,"activeCount":100},[],{"trials":2610,"activeCount":100},[],{"trials":2612,"activeCount":100},[],{"intervention":2371,"totalTrials":96,"cells":2614},{"EARLY_PHASE1":2615,"PHASE1":2617,"PHASE2":2619,"PHASE3":2625,"PHASE4":2627,"NA":2629},{"trials":2616,"activeCount":100},[],{"trials":2618,"activeCount":100},[],{"trials":2620,"activeCount":100},[2621],{"nctId":2362,"briefTitle":2363,"status":259,"phases":2622,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":100,"conditions":2623,"interventions":2624},[90],[2368],[2370,2353,2371,2372,2373,2374,2375,2376],{"trials":2626,"activeCount":100},[],{"trials":2628,"activeCount":100},[],{"trials":2630,"activeCount":100},[],{"intervention":2373,"totalTrials":96,"cells":2632},{"EARLY_PHASE1":2633,"PHASE1":2635,"PHASE2":2637,"PHASE3":2643,"PHASE4":2645,"NA":2647},{"trials":2634,"activeCount":100},[],{"trials":2636,"activeCount":100},[],{"trials":2638,"activeCount":100},[2639],{"nctId":2362,"briefTitle":2363,"status":259,"phases":2640,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":100,"conditions":2641,"interventions":2642},[90],[2368],[2370,2353,2371,2372,2373,2374,2375,2376],{"trials":2644,"activeCount":100},[],{"trials":2646,"activeCount":100},[],{"trials":2648,"activeCount":100},[],{"intervention":2374,"totalTrials":96,"cells":2650},{"EARLY_PHASE1":2651,"PHASE1":2653,"PHASE2":2655,"PHASE3":2661,"PHASE4":2663,"NA":2665},{"trials":2652,"activeCount":100},[],{"trials":2654,"activeCount":100},[],{"trials":2656,"activeCount":100},[2657],{"nctId":2362,"briefTitle":2363,"status":259,"phases":2658,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":100,"conditions":2659,"interventions":2660},[90],[2368],[2370,2353,2371,2372,2373,2374,2375,2376],{"trials":2662,"activeCount":100},[],{"trials":2664,"activeCount":100},[],{"trials":2666,"activeCount":100},[],{"intervention":2375,"totalTrials":96,"cells":2668},{"EARLY_PHASE1":2669,"PHASE1":2671,"PHASE2":2673,"PHASE3":2679,"PHASE4":2681,"NA":2683},{"trials":2670,"activeCount":100},[],{"trials":2672,"activeCount":100},[],{"trials":2674,"activeCount":100},[2675],{"nctId":2362,"briefTitle":2363,"status":259,"phases":2676,"primaryCompletion":2365,"completion":2365,"start":2366,"enrollment":100,"conditions":2677,"interventions":2678},[90],[2368],[2370,2353,2371,2372,2373,2374,2375,2376],{"trials":2680,"activeCount":100},[],{"trials":2682,"activeCount":100},[],{"trials":2684,"activeCount":100},[],{"intervention":2453,"totalTrials":96,"cells":2686},{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2697,"PHASE4":2699,"NA":2701},{"trials":2688,"activeCount":100},[],{"trials":2690,"activeCount":100},[],{"trials":2692,"activeCount":100},[2693],{"nctId":2448,"briefTitle":2449,"status":259,"phases":2694,"enrollment":100,"conditions":2695,"interventions":2696},[90],[885],[2453,2454,2455,2439],{"trials":2698,"activeCount":100},[],{"trials":2700,"activeCount":100},[],{"trials":2702,"activeCount":100},[],{"intervention":2454,"totalTrials":96,"cells":2704},{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2715,"PHASE4":2717,"NA":2719},{"trials":2706,"activeCount":100},[],{"trials":2708,"activeCount":100},[],{"trials":2710,"activeCount":100},[2711],{"nctId":2448,"briefTitle":2449,"status":259,"phases":2712,"enrollment":100,"conditions":2713,"interventions":2714},[90],[885],[2453,2454,2455,2439],{"trials":2716,"activeCount":100},[],{"trials":2718,"activeCount":100},[],{"trials":2720,"activeCount":100},[],{"intervention":2455,"totalTrials":96,"cells":2722},{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2724,"activeCount":100},[],{"trials":2726,"activeCount":100},[],{"trials":2728,"activeCount":100},[2729],{"nctId":2448,"briefTitle":2449,"status":259,"phases":2730,"enrollment":100,"conditions":2731,"interventions":2732},[90],[885],[2453,2454,2455,2439],{"trials":2734,"activeCount":100},[],{"trials":2736,"activeCount":100},[],{"trials":2738,"activeCount":100},[],{"intervention":2740,"totalTrials":96,"cells":2741},"Policosanol",{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2746,"PHASE3":2758,"PHASE4":2760,"NA":2762},{"trials":2743,"activeCount":100},[],{"trials":2745,"activeCount":100},[],{"trials":2747,"activeCount":100},[2748],{"nctId":2749,"briefTitle":2750,"status":276,"phases":2751,"primaryCompletion":1378,"completion":1551,"start":2752,"enrollment":2753,"conditions":2754,"interventions":2757},"NCT00312923","Preliminary Study of Safety and Efficacy of Policosanol",[90],"2005-09",54,[2755,2756],"Dyslipidemia","HIV Infections",[2740],{"trials":2759,"activeCount":100},[],{"trials":2761,"activeCount":100},[],{"trials":2763,"activeCount":100},[],{"intervention":2465,"totalTrials":96,"cells":2765},{"EARLY_PHASE1":2766,"PHASE1":2768,"PHASE2":2770,"PHASE3":2776,"PHASE4":2778,"NA":2780},{"trials":2767,"activeCount":100},[],{"trials":2769,"activeCount":100},[],{"trials":2771,"activeCount":100},[2772],{"nctId":2457,"briefTitle":2458,"status":276,"phases":2773,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":2462,"conditions":2774,"interventions":2775},[90],[18],[2465,2466],{"trials":2777,"activeCount":100},[],{"trials":2779,"activeCount":100},[],{"trials":2781,"activeCount":100},[],{"intervention":2783,"totalTrials":96,"cells":2784},"Panhematin",{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2801,"PHASE4":2803,"NA":2805},{"trials":2786,"activeCount":100},[],{"trials":2788,"activeCount":100},[],{"trials":2790,"activeCount":100},[2791],{"nctId":2792,"briefTitle":2793,"status":308,"phases":2794,"primaryCompletion":2795,"completion":2796,"start":2797,"enrollment":31,"conditions":2798,"interventions":2800},"NCT00467610","Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS",[90],"2008-12","2009-01","2007-05",[2799],"Myelodysplastic Syndrome",[2783],{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[],{"trials":2806,"activeCount":100},[],{"intervention":2808,"totalTrials":96,"cells":2809},"AXL1717",{"EARLY_PHASE1":2810,"PHASE1":2812,"PHASE2":2814,"PHASE3":2828,"PHASE4":2830,"NA":2832},{"trials":2811,"activeCount":100},[],{"trials":2813,"activeCount":100},[],{"trials":2815,"activeCount":100},[2816],{"nctId":2817,"briefTitle":2818,"status":308,"phases":2819,"primaryCompletion":984,"completion":984,"start":1195,"enrollment":1266,"conditions":2820,"interventions":2827},"NCT01721577","Phase I\u002FII Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas",[89,90],[2821,2822,2823,2824,2825,2826],"Glioblastoma","Gliosarcoma","Anaplastic Astrocytoma","Anaplastic Oligodendroglioma","Anaplastic Oligoastrocytoma","Anaplastic Ependymoma",[2808],{"trials":2829,"activeCount":100},[],{"trials":2831,"activeCount":100},[],{"trials":2833,"activeCount":100},[],{"intervention":2835,"totalTrials":96,"cells":2836},"citocoline",{"EARLY_PHASE1":2837,"PHASE1":2839,"PHASE2":2841,"PHASE3":2852,"PHASE4":2854,"NA":2856},{"trials":2838,"activeCount":100},[],{"trials":2840,"activeCount":100},[],{"trials":2842,"activeCount":100},[2843],{"nctId":2844,"briefTitle":2845,"status":276,"phases":2846,"primaryCompletion":2847,"completion":2847,"start":2848,"enrollment":1266,"conditions":2849,"interventions":2851},"NCT02197104","Citocoline for Treatment in Fragile X-associated Tremor\u002FAtaxia Syndrome",[90],"2017-01","2015-01",[2850],"Fragile X Tremor\u002FAtaxia Syndrome",[2835],{"trials":2853,"activeCount":100},[],{"trials":2855,"activeCount":100},[],{"trials":2857,"activeCount":100},[],{"intervention":2859,"totalTrials":96,"cells":2860},"pregabalin",{"EARLY_PHASE1":2861,"PHASE1":2863,"PHASE2":2865,"PHASE3":2876,"PHASE4":2878,"NA":2880},{"trials":2862,"activeCount":100},[],{"trials":2864,"activeCount":100},[],{"trials":2866,"activeCount":100},[2867],{"nctId":2868,"briefTitle":2869,"status":276,"phases":2870,"primaryCompletion":2871,"completion":2871,"start":1292,"enrollment":2872,"conditions":2873,"interventions":2875},"NCT00558753","Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset CRPS After TKA",[90],"2010-06",240,[2874],"CRPS",[2859],{"trials":2877,"activeCount":100},[],{"trials":2879,"activeCount":100},[],{"trials":2881,"activeCount":100},[],{"intervention":2883,"totalTrials":96,"cells":2884},"Active fructo-oligosaccharide",{"EARLY_PHASE1":2885,"PHASE1":2887,"PHASE2":2889,"PHASE3":2901,"PHASE4":2903,"NA":2905},{"trials":2886,"activeCount":100},[],{"trials":2888,"activeCount":100},[],{"trials":2890,"activeCount":100},[2891],{"nctId":2892,"briefTitle":2893,"status":276,"phases":2894,"primaryCompletion":2895,"completion":2895,"start":2896,"enrollment":1814,"conditions":2897,"interventions":2900},"NCT00343642","Dietary Treatment of Crohn's Disease",[89,90],"2012-10","2006-09",[2898,2899],"Crohn's Disease","Inflammatory Bowel Disease",[2883],{"trials":2902,"activeCount":100},[],{"trials":2904,"activeCount":100},[],{"trials":2906,"activeCount":100},[],{"intervention":831,"totalTrials":96,"cells":2908},{"EARLY_PHASE1":2909,"PHASE1":2911,"PHASE2":2913,"PHASE3":2919,"PHASE4":2921,"NA":2923},{"trials":2910,"activeCount":100},[],{"trials":2912,"activeCount":100},[],{"trials":2914,"activeCount":100},[2915],{"nctId":825,"briefTitle":826,"status":308,"phases":2916,"primaryCompletion":819,"completion":819,"start":828,"enrollment":34,"conditions":2917,"interventions":2918},[90],[822],[807,831,832,833,834,835,836],{"trials":2920,"activeCount":100},[],{"trials":2922,"activeCount":100},[],{"trials":2924,"activeCount":100},[],{"intervention":832,"totalTrials":96,"cells":2926},{"EARLY_PHASE1":2927,"PHASE1":2929,"PHASE2":2931,"PHASE3":2937,"PHASE4":2939,"NA":2941},{"trials":2928,"activeCount":100},[],{"trials":2930,"activeCount":100},[],{"trials":2932,"activeCount":100},[2933],{"nctId":825,"briefTitle":826,"status":308,"phases":2934,"primaryCompletion":819,"completion":819,"start":828,"enrollment":34,"conditions":2935,"interventions":2936},[90],[822],[807,831,832,833,834,835,836],{"trials":2938,"activeCount":100},[],{"trials":2940,"activeCount":100},[],{"trials":2942,"activeCount":100},[],{"intervention":833,"totalTrials":96,"cells":2944},{"EARLY_PHASE1":2945,"PHASE1":2947,"PHASE2":2949,"PHASE3":2955,"PHASE4":2957,"NA":2959},{"trials":2946,"activeCount":100},[],{"trials":2948,"activeCount":100},[],{"trials":2950,"activeCount":100},[2951],{"nctId":825,"briefTitle":826,"status":308,"phases":2952,"primaryCompletion":819,"completion":819,"start":828,"enrollment":34,"conditions":2953,"interventions":2954},[90],[822],[807,831,832,833,834,835,836],{"trials":2956,"activeCount":100},[],{"trials":2958,"activeCount":100},[],{"trials":2960,"activeCount":100},[],{"intervention":834,"totalTrials":96,"cells":2962},{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2973,"PHASE4":2975,"NA":2977},{"trials":2964,"activeCount":100},[],{"trials":2966,"activeCount":100},[],{"trials":2968,"activeCount":100},[2969],{"nctId":825,"briefTitle":826,"status":308,"phases":2970,"primaryCompletion":819,"completion":819,"start":828,"enrollment":34,"conditions":2971,"interventions":2972},[90],[822],[807,831,832,833,834,835,836],{"trials":2974,"activeCount":100},[],{"trials":2976,"activeCount":100},[],{"trials":2978,"activeCount":100},[],{"intervention":835,"totalTrials":96,"cells":2980},{"EARLY_PHASE1":2981,"PHASE1":2983,"PHASE2":2985,"PHASE3":2991,"PHASE4":2993,"NA":2995},{"trials":2982,"activeCount":100},[],{"trials":2984,"activeCount":100},[],{"trials":2986,"activeCount":100},[2987],{"nctId":825,"briefTitle":826,"status":308,"phases":2988,"primaryCompletion":819,"completion":819,"start":828,"enrollment":34,"conditions":2989,"interventions":2990},[90],[822],[807,831,832,833,834,835,836],{"trials":2992,"activeCount":100},[],{"trials":2994,"activeCount":100},[],{"trials":2996,"activeCount":100},[],{"intervention":836,"totalTrials":96,"cells":2998},{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3003,"PHASE3":3009,"PHASE4":3011,"NA":3013},{"trials":3000,"activeCount":100},[],{"trials":3002,"activeCount":100},[],{"trials":3004,"activeCount":100},[3005],{"nctId":825,"briefTitle":826,"status":308,"phases":3006,"primaryCompletion":819,"completion":819,"start":828,"enrollment":34,"conditions":3007,"interventions":3008},[90],[822],[807,831,832,833,834,835,836],{"trials":3010,"activeCount":100},[],{"trials":3012,"activeCount":100},[],{"trials":3014,"activeCount":100},[],{"intervention":3016,"totalTrials":96,"cells":3017},"ranibizumab",{"EARLY_PHASE1":3018,"PHASE1":3020,"PHASE2":3022,"PHASE3":3032,"PHASE4":3034,"NA":3036},{"trials":3019,"activeCount":100},[],{"trials":3021,"activeCount":100},[],{"trials":3023,"activeCount":100},[3024],{"nctId":3025,"briefTitle":3026,"status":276,"phases":3027,"primaryCompletion":3028,"completion":3028,"start":112,"enrollment":22,"conditions":3029,"interventions":3031},"NCT00606138","Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging",[89,90],"2010-10",[3030],"Proliferative Diabetic Retinopathy",[3016],{"trials":3033,"activeCount":100},[],{"trials":3035,"activeCount":100},[],{"trials":3037,"activeCount":100},[],{"intervention":3039,"totalTrials":96,"cells":3040},"thalidomide",{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3058,"PHASE4":3060,"NA":3062},{"trials":3042,"activeCount":100},[],{"trials":3044,"activeCount":100},[],{"trials":3046,"activeCount":100},[3047],{"nctId":3048,"briefTitle":3049,"status":308,"phases":3050,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":34,"conditions":3054,"interventions":3056},"NCT00014443","Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma",[90],"2003-08","2003-12","2000-08",[3055],"Brain and Central Nervous System Tumors",[3039,3057],"topotecan hydrochloride",{"trials":3059,"activeCount":100},[],{"trials":3061,"activeCount":100},[],{"trials":3063,"activeCount":100},[],{"intervention":3057,"totalTrials":96,"cells":3065},{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3070,"PHASE3":3076,"PHASE4":3078,"NA":3080},{"trials":3067,"activeCount":100},[],{"trials":3069,"activeCount":100},[],{"trials":3071,"activeCount":100},[3072],{"nctId":3048,"briefTitle":3049,"status":308,"phases":3073,"primaryCompletion":3051,"completion":3052,"start":3053,"enrollment":34,"conditions":3074,"interventions":3075},[90],[3055],[3039,3057],{"trials":3077,"activeCount":100},[],{"trials":3079,"activeCount":100},[],{"trials":3081,"activeCount":100},[],{"intervention":3083,"totalTrials":96,"cells":3084},"Bortezomib and Tositumomab I-131",{"EARLY_PHASE1":3085,"PHASE1":3087,"PHASE2":3089,"PHASE3":3099,"PHASE4":3101,"NA":3103},{"trials":3086,"activeCount":100},[],{"trials":3088,"activeCount":100},[],{"trials":3090,"activeCount":100},[3091],{"nctId":3092,"briefTitle":3093,"status":308,"phases":3094,"primaryCompletion":3095,"completion":3095,"start":2797,"enrollment":96,"conditions":3096,"interventions":3098},"NCT00479167","A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma",[90],"2008-09",[3097],"Follicular Lymphoma",[3083],{"trials":3100,"activeCount":100},[],{"trials":3102,"activeCount":100},[],{"trials":3104,"activeCount":100},[],{"intervention":871,"totalTrials":96,"cells":3106},{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3117,"PHASE4":3119,"NA":3121},{"trials":3108,"activeCount":100},[],{"trials":3110,"activeCount":100},[],{"trials":3112,"activeCount":100},[3113],{"nctId":862,"briefTitle":863,"status":308,"phases":3114,"primaryCompletion":819,"completion":819,"start":865,"enrollment":866,"conditions":3115,"interventions":3116},[90],[868,869],[871,853],{"trials":3118,"activeCount":100},[],{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[],{"intervention":3124,"totalTrials":96,"cells":3125},"Erlotinib",{"EARLY_PHASE1":3126,"PHASE1":3128,"PHASE2":3130,"PHASE3":3140,"PHASE4":3142,"NA":3144},{"trials":3127,"activeCount":100},[],{"trials":3129,"activeCount":100},[],{"trials":3131,"activeCount":100},[3132],{"nctId":3133,"briefTitle":3134,"status":308,"phases":3135,"primaryCompletion":1446,"completion":1446,"start":3136,"enrollment":19,"conditions":3137,"interventions":3139},"NCT00597597","Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer",[90],"2007-04",[3138],"Metastatic Breast Cancer",[3124],{"trials":3141,"activeCount":100},[],{"trials":3143,"activeCount":100},[],{"trials":3145,"activeCount":100},[],{"intervention":3147,"totalTrials":96,"cells":3148},"Nasal Mometasone Rinse",{"EARLY_PHASE1":3149,"PHASE1":3151,"PHASE2":3164,"PHASE3":3166,"PHASE4":3168,"NA":3170},{"trials":3150,"activeCount":100},[],{"trials":3152,"activeCount":100},[3153],{"nctId":3154,"briefTitle":3155,"status":276,"phases":3156,"primaryCompletion":3157,"completion":3158,"start":3159,"enrollment":3160,"conditions":3161,"interventions":3163},"NCT03979209","Potential for Cortisol Suppression With the Use of High Volume Nasal Mometasone Irrigations in Varying Dosages.",[89],"2021-06-22","2022-07-28","2019-01-14",16,[3162],"Chronic Rhinosinusitis (Diagnosis)",[3147],{"trials":3165,"activeCount":100},[],{"trials":3167,"activeCount":100},[],{"trials":3169,"activeCount":100},[],{"trials":3171,"activeCount":100},[],{"intervention":3173,"totalTrials":96,"cells":3174},"Oral Ketamine",{"EARLY_PHASE1":3175,"PHASE1":3177,"PHASE2":3190,"PHASE3":3192,"PHASE4":3194,"NA":3196},{"trials":3176,"activeCount":100},[],{"trials":3178,"activeCount":100},[3179],{"nctId":3180,"briefTitle":3181,"status":308,"phases":3182,"primaryCompletion":3183,"completion":3184,"start":2848,"enrollment":34,"conditions":3185,"interventions":3189},"NCT02341963","A Pilot Clinical Trial of Oral Ketamine for Acute Pain Management After Amputation Surgery",[89],"2020-12","2021-01",[3186,3187,3188],"Acute Pain Management","Analgesic, Nonopioid","Amputation of Lower Extremity, All Causes",[3173],{"trials":3191,"activeCount":100},[],{"trials":3193,"activeCount":100},[],{"trials":3195,"activeCount":100},[],{"trials":3197,"activeCount":100},[],{"intervention":3199,"totalTrials":96,"cells":3200},"Fluzone Quadrivalent",{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3213,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3202,"activeCount":100},[],{"trials":3204,"activeCount":100},[3205],{"nctId":3206,"briefTitle":3207,"status":259,"phases":3208,"primaryCompletion":3209,"completion":342,"start":202,"enrollment":100,"conditions":3210,"interventions":3212},"NCT06229392","A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer",[89],"2027-06-01",[1269,3211],"Breast Cancer Triple Negative",[3199],{"trials":3214,"activeCount":100},[],{"trials":3216,"activeCount":100},[],{"trials":3218,"activeCount":100},[],{"trials":3220,"activeCount":100},[],{"intervention":3222,"totalTrials":96,"cells":3223},"Aspirin Challenge",{"EARLY_PHASE1":3224,"PHASE1":3235,"PHASE2":3237,"PHASE3":3239,"PHASE4":3241,"NA":3243},{"trials":3225,"activeCount":100},[3226],{"nctId":3227,"briefTitle":3228,"status":276,"phases":3229,"primaryCompletion":2101,"completion":2101,"start":3230,"enrollment":3231,"conditions":3232,"interventions":3234},"NCT05428072","Alcohol, Gut Leakiness, & Liver Disease",[88],"2003-01",195,[3233],"Alcoholic Liver Disease",[3222],{"trials":3236,"activeCount":100},[],{"trials":3238,"activeCount":100},[],{"trials":3240,"activeCount":100},[],{"trials":3242,"activeCount":100},[],{"trials":3244,"activeCount":100},[],{"intervention":3246,"totalTrials":96,"cells":3247},"Loperamide",{"EARLY_PHASE1":3248,"PHASE1":3259,"PHASE2":3261,"PHASE3":3263,"PHASE4":3265,"NA":3267},{"trials":3249,"activeCount":100},[3250],{"nctId":3251,"briefTitle":3252,"status":276,"phases":3253,"primaryCompletion":984,"completion":984,"start":2101,"enrollment":3254,"conditions":3255,"interventions":3257},"NCT02711891","Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing",[88],34,[3256],"Pain",[3246,3258],"Drug, placebo gel",{"trials":3260,"activeCount":100},[],{"trials":3262,"activeCount":100},[],{"trials":3264,"activeCount":100},[],{"trials":3266,"activeCount":100},[],{"trials":3268,"activeCount":100},[],{"intervention":3258,"totalTrials":96,"cells":3270},{"EARLY_PHASE1":3271,"PHASE1":3277,"PHASE2":3279,"PHASE3":3281,"PHASE4":3283,"NA":3285},{"trials":3272,"activeCount":100},[3273],{"nctId":3251,"briefTitle":3252,"status":276,"phases":3274,"primaryCompletion":984,"completion":984,"start":2101,"enrollment":3254,"conditions":3275,"interventions":3276},[88],[3256],[3246,3258],{"trials":3278,"activeCount":100},[],{"trials":3280,"activeCount":100},[],{"trials":3282,"activeCount":100},[],{"trials":3284,"activeCount":100},[],{"trials":3286,"activeCount":100},[],{"intervention":3288,"totalTrials":96,"cells":3289},"40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine",{"EARLY_PHASE1":3290,"PHASE1":3303,"PHASE2":3305,"PHASE3":3307,"PHASE4":3309,"NA":3311},{"trials":3291,"activeCount":100},[3292],{"nctId":3293,"briefTitle":3294,"status":259,"phases":3295,"primaryCompletion":3296,"completion":3296,"start":3297,"enrollment":100,"conditions":3298,"interventions":3300},"NCT02995083","Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial",[88],"2018-01","2017-06",[3299],"Symptomatic Osteoarthritis of the Knee",[3288,3301,3302],"Normal Saline 10 ml","Air 10 ml",{"trials":3304,"activeCount":100},[],{"trials":3306,"activeCount":100},[],{"trials":3308,"activeCount":100},[],{"trials":3310,"activeCount":100},[],{"trials":3312,"activeCount":100},[],{"intervention":3301,"totalTrials":96,"cells":3314},{"EARLY_PHASE1":3315,"PHASE1":3321,"PHASE2":3323,"PHASE3":3325,"PHASE4":3327,"NA":3329},{"trials":3316,"activeCount":100},[3317],{"nctId":3293,"briefTitle":3294,"status":259,"phases":3318,"primaryCompletion":3296,"completion":3296,"start":3297,"enrollment":100,"conditions":3319,"interventions":3320},[88],[3299],[3288,3301,3302],{"trials":3322,"activeCount":100},[],{"trials":3324,"activeCount":100},[],{"trials":3326,"activeCount":100},[],{"trials":3328,"activeCount":100},[],{"trials":3330,"activeCount":100},[],{"intervention":3302,"totalTrials":96,"cells":3332},{"EARLY_PHASE1":3333,"PHASE1":3339,"PHASE2":3341,"PHASE3":3343,"PHASE4":3345,"NA":3347},{"trials":3334,"activeCount":100},[3335],{"nctId":3293,"briefTitle":3294,"status":259,"phases":3336,"primaryCompletion":3296,"completion":3296,"start":3297,"enrollment":100,"conditions":3337,"interventions":3338},[88],[3299],[3288,3301,3302],{"trials":3340,"activeCount":100},[],{"trials":3342,"activeCount":100},[],{"trials":3344,"activeCount":100},[],{"trials":3346,"activeCount":100},[],{"trials":3348,"activeCount":100},[],{"intervention":480,"totalTrials":453,"cells":3350},{"EARLY_PHASE1":3351,"PHASE1":3353,"PHASE2":3355,"PHASE3":3357,"PHASE4":3363,"NA":3369},{"trials":3352,"activeCount":100},[],{"trials":3354,"activeCount":100},[],{"trials":3356,"activeCount":100},[],{"trials":3358,"activeCount":100},[3359],{"nctId":468,"briefTitle":469,"status":259,"phases":3360,"primaryCompletion":471,"completion":471,"start":472,"enrollment":100,"conditions":3361,"interventions":3362},[91],[474,475],[477,478,479,480,86,481,482,483,484,485,486,487,488],{"trials":3364,"activeCount":100},[3365],{"nctId":492,"briefTitle":493,"status":259,"phases":3366,"primaryCompletion":495,"completion":495,"start":496,"enrollment":100,"conditions":3367,"interventions":3368},[92],[15,498],[500,501,480,86,502],{"trials":3370,"activeCount":100},[3371],{"nctId":3372,"briefTitle":3373,"status":308,"phases":3374,"primaryCompletion":3375,"completion":3375,"start":3376,"enrollment":453,"conditions":3377,"interventions":3380},"NCT01997567","Preemptive Femoral & Lateral Femoral Cutaneous Nerve Blocks for THA Acute Pain",[93],"2014-03","2013-07",[3378,3379],"Internal Derangement of Hip","Acetabular Labrum Tear",[480],{"intervention":3382,"totalTrials":96,"cells":3383},"Palbociclib",{"EARLY_PHASE1":3384,"PHASE1":3386,"PHASE2":3388,"PHASE3":3390,"PHASE4":3392,"NA":3394},{"trials":3385,"activeCount":100},[],{"trials":3387,"activeCount":100},[],{"trials":3389,"activeCount":100},[],{"trials":3391,"activeCount":100},[],{"trials":3393,"activeCount":100},[],{"trials":3395,"activeCount":100},[3396],{"nctId":3397,"briefTitle":3398,"status":276,"phases":3399,"primaryCompletion":3400,"completion":3400,"start":3401,"enrollment":3402,"conditions":3403,"interventions":3407},"NCT03285568","Patterns of Prescribing and Monitoring of Palbociclib",[],"2016-12-30","2015-02-03",67,[3138,3404,3405,3406],"Advanced Breast Cancer","Estrogen Receptor-positive Breast Cancer","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",[3382],{"intervention":441,"totalTrials":96,"cells":3409},{"EARLY_PHASE1":3410,"PHASE1":3412,"PHASE2":3414,"PHASE3":3416,"PHASE4":3418,"NA":3420},{"trials":3411,"activeCount":100},[],{"trials":3413,"activeCount":100},[],{"trials":3415,"activeCount":100},[],{"trials":3417,"activeCount":100},[],{"trials":3419,"activeCount":100},[],{"trials":3421,"activeCount":100},[3422],{"nctId":431,"briefTitle":432,"status":259,"phases":3423,"primaryCompletion":434,"completion":435,"start":436,"enrollment":100,"conditions":3424,"interventions":3425},[93],[438,439],[441,272],{"intervention":3427,"totalTrials":96,"cells":3428},"Antibiotic",{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3433,"PHASE3":3435,"PHASE4":3437,"NA":3439},{"trials":3430,"activeCount":100},[],{"trials":3432,"activeCount":100},[],{"trials":3434,"activeCount":100},[],{"trials":3436,"activeCount":100},[],{"trials":3438,"activeCount":100},[],{"trials":3440,"activeCount":100},[3441],{"nctId":3442,"briefTitle":3443,"status":259,"phases":3444,"primaryCompletion":3445,"completion":3445,"start":3446,"enrollment":100,"conditions":3447,"interventions":3449},"NCT03551847","The Effect of Oral Antibiotics on Synovial Fluid and Differential for the Diagnosis of Infection",[93],"2019-11-05","2011-07-01",[3448],"Infection",[3427,3450],"No antibiotics",{"intervention":3450,"totalTrials":96,"cells":3452},{"EARLY_PHASE1":3453,"PHASE1":3455,"PHASE2":3457,"PHASE3":3459,"PHASE4":3461,"NA":3463},{"trials":3454,"activeCount":100},[],{"trials":3456,"activeCount":100},[],{"trials":3458,"activeCount":100},[],{"trials":3460,"activeCount":100},[],{"trials":3462,"activeCount":100},[],{"trials":3464,"activeCount":100},[3465],{"nctId":3442,"briefTitle":3443,"status":259,"phases":3466,"primaryCompletion":3445,"completion":3445,"start":3446,"enrollment":100,"conditions":3467,"interventions":3468},[93],[3448],[3427,3450],{"intervention":3470,"totalTrials":96,"cells":3471},"Omegaven",{"EARLY_PHASE1":3472,"PHASE1":3474,"PHASE2":3476,"PHASE3":3478,"PHASE4":3480,"NA":3482},{"trials":3473,"activeCount":100},[],{"trials":3475,"activeCount":100},[],{"trials":3477,"activeCount":100},[],{"trials":3479,"activeCount":100},[],{"trials":3481,"activeCount":100},[],{"trials":3483,"activeCount":100},[3484],{"nctId":3485,"briefTitle":3486,"status":3487,"phases":3488,"conditions":3489,"interventions":3492},"NCT02780193","Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury","APPROVED_FOR_MARKETING",[],[3490,3491],"Cholestasis","Total Parenteral Nutrition-induced Cholestasis",[3470],{"intervention":3494,"totalTrials":96,"cells":3495},"Mesenchymal stem cell augmentation in rotator cuff repair",{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3500,"PHASE3":3502,"PHASE4":3504,"NA":3506},{"trials":3497,"activeCount":100},[],{"trials":3499,"activeCount":100},[],{"trials":3501,"activeCount":100},[],{"trials":3503,"activeCount":100},[],{"trials":3505,"activeCount":100},[],{"trials":3507,"activeCount":100},[3508],{"nctId":3509,"briefTitle":3510,"status":276,"phases":3511,"primaryCompletion":3512,"completion":3513,"start":3514,"enrollment":3515,"conditions":3516,"interventions":3518},"NCT02484950","Mesenchymal Stem Cell Augmentation in Patients Undergoing Arthroscopic Rotator Cuff Repair",[93],"2024-05-01","2024-06-27","2015-11-15",62,[3517],"Full Thickness Rotator Cuff Tear",[3494],{"intervention":3520,"totalTrials":96,"cells":3521},"3.15% chlorhexidine\u002F70% isopropyl alcohol",{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3526,"PHASE3":3528,"PHASE4":3530,"NA":3532},{"trials":3523,"activeCount":100},[],{"trials":3525,"activeCount":100},[],{"trials":3527,"activeCount":100},[],{"trials":3529,"activeCount":100},[],{"trials":3531,"activeCount":100},[],{"trials":3533,"activeCount":100},[3534],{"nctId":3535,"briefTitle":3536,"status":276,"phases":3537,"primaryCompletion":881,"completion":881,"start":985,"enrollment":3538,"conditions":3539,"interventions":3541},"NCT01563406","Hub Cleansing to Prevent Hub Infection",[93],149,[3540],"Bacteremia",[3520,3542],"70% isopropyl alcohol",{"intervention":3542,"totalTrials":96,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3547,"PHASE2":3549,"PHASE3":3551,"PHASE4":3553,"NA":3555},{"trials":3546,"activeCount":100},[],{"trials":3548,"activeCount":100},[],{"trials":3550,"activeCount":100},[],{"trials":3552,"activeCount":100},[],{"trials":3554,"activeCount":100},[],{"trials":3556,"activeCount":100},[3557],{"nctId":3535,"briefTitle":3536,"status":276,"phases":3558,"primaryCompletion":881,"completion":881,"start":985,"enrollment":3538,"conditions":3559,"interventions":3560},[93],[3540],[3520,3542],{"intervention":3562,"totalTrials":96,"cells":3563},"Oral Tranexamic Acid",{"EARLY_PHASE1":3564,"PHASE1":3566,"PHASE2":3568,"PHASE3":3570,"PHASE4":3572,"NA":3574},{"trials":3565,"activeCount":100},[],{"trials":3567,"activeCount":100},[],{"trials":3569,"activeCount":100},[],{"trials":3571,"activeCount":100},[],{"trials":3573,"activeCount":100},[],{"trials":3575,"activeCount":100},[3576],{"nctId":3577,"briefTitle":3578,"status":276,"phases":3579,"primaryCompletion":1813,"completion":1813,"start":3580,"enrollment":3581,"conditions":3582,"interventions":3585},"NCT02233101","Oral vs. Intravenous TXA Study Proposal: TJA",[93],"2014-06",167,[3583,3584],"Blood Loss After Primary Total Joint Arthroplasty","Need for Blood Transfusion After Total Joint Arthroplasty",[3562,3586],"Intravenous Tranexamic Acid",{"intervention":3586,"totalTrials":96,"cells":3588},{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3593,"PHASE3":3595,"PHASE4":3597,"NA":3599},{"trials":3590,"activeCount":100},[],{"trials":3592,"activeCount":100},[],{"trials":3594,"activeCount":100},[],{"trials":3596,"activeCount":100},[],{"trials":3598,"activeCount":100},[],{"trials":3600,"activeCount":100},[3601],{"nctId":3577,"briefTitle":3578,"status":276,"phases":3602,"primaryCompletion":1813,"completion":1813,"start":3580,"enrollment":3581,"conditions":3603,"interventions":3604},[93],[3583,3584],[3562,3586],{"intervention":3606,"totalTrials":96,"cells":3607},"fixed-dose activated prothrombin complex concentrate",{"EARLY_PHASE1":3608,"PHASE1":3610,"PHASE2":3612,"PHASE3":3614,"PHASE4":3616,"NA":3618},{"trials":3609,"activeCount":100},[],{"trials":3611,"activeCount":100},[],{"trials":3613,"activeCount":100},[],{"trials":3615,"activeCount":100},[],{"trials":3617,"activeCount":100},[],{"trials":3619,"activeCount":100},[3620],{"nctId":3621,"briefTitle":3622,"status":276,"phases":3623,"primaryCompletion":3624,"completion":3624,"start":3625,"enrollment":3626,"conditions":3627,"interventions":3629},"NCT02565836","Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed",[],"2016-09-30","2015-10",342,[3628],"Hemorrhage",[3606,3630],"variable-dose inactivated prothrombin complex concentrate",{"intervention":3630,"totalTrials":96,"cells":3632},{"EARLY_PHASE1":3633,"PHASE1":3635,"PHASE2":3637,"PHASE3":3639,"PHASE4":3641,"NA":3643},{"trials":3634,"activeCount":100},[],{"trials":3636,"activeCount":100},[],{"trials":3638,"activeCount":100},[],{"trials":3640,"activeCount":100},[],{"trials":3642,"activeCount":100},[],{"trials":3644,"activeCount":100},[3645],{"nctId":3621,"briefTitle":3622,"status":276,"phases":3646,"primaryCompletion":3624,"completion":3624,"start":3625,"enrollment":3626,"conditions":3647,"interventions":3648},[],[3628],[3606,3630],{"intervention":3650,"totalTrials":96,"cells":3651},"Platelet-rich Plasma",{"EARLY_PHASE1":3652,"PHASE1":3654,"PHASE2":3656,"PHASE3":3658,"PHASE4":3660,"NA":3662},{"trials":3653,"activeCount":100},[],{"trials":3655,"activeCount":100},[],{"trials":3657,"activeCount":100},[],{"trials":3659,"activeCount":100},[],{"trials":3661,"activeCount":100},[],{"trials":3663,"activeCount":100},[3664],{"nctId":3665,"briefTitle":3666,"status":276,"phases":3667,"primaryCompletion":3668,"completion":3668,"start":845,"enrollment":3669,"conditions":3670,"interventions":3672},"NCT02588872","Hyaluronic Acid vs Platelet Rich Plasma: Effects on Clinical Outcomes and Intra-articular Biology for the Treatment of Knee Osteoarthritis",[93],"2015-04",111,[3671],"Osteoarthritis, Knee",[3650,3673],"Hyaluronic Acid",{"intervention":3673,"totalTrials":96,"cells":3675},{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3680,"PHASE3":3682,"PHASE4":3684,"NA":3686},{"trials":3677,"activeCount":100},[],{"trials":3679,"activeCount":100},[],{"trials":3681,"activeCount":100},[],{"trials":3683,"activeCount":100},[],{"trials":3685,"activeCount":100},[],{"trials":3687,"activeCount":100},[3688],{"nctId":3665,"briefTitle":3666,"status":276,"phases":3689,"primaryCompletion":3668,"completion":3668,"start":845,"enrollment":3669,"conditions":3690,"interventions":3691},[93],[3671],[3650,3673],{"intervention":3693,"totalTrials":96,"cells":3694},"Tranexamic Acid",{"EARLY_PHASE1":3695,"PHASE1":3697,"PHASE2":3699,"PHASE3":3701,"PHASE4":3703,"NA":3705},{"trials":3696,"activeCount":100},[],{"trials":3698,"activeCount":100},[],{"trials":3700,"activeCount":100},[],{"trials":3702,"activeCount":100},[],{"trials":3704,"activeCount":100},[],{"trials":3706,"activeCount":100},[3707],{"nctId":3708,"briefTitle":3709,"status":276,"phases":3710,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3713,"conditions":3714,"interventions":3719},"NCT02569658","Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty",[93],"2017-04","2015-09",110,[3715,3716,3717,3718,3693],"Blood Loss","Anatomic Total Shoulder Arthroplasty","Reverse Total Shoulder Arthroplasty","Transfusion",[3693],{"intervention":329,"totalTrials":96,"cells":3721},{"EARLY_PHASE1":3722,"PHASE1":3724,"PHASE2":3726,"PHASE3":3728,"PHASE4":3730,"NA":3732},{"trials":3723,"activeCount":100},[],{"trials":3725,"activeCount":100},[],{"trials":3727,"activeCount":100},[],{"trials":3729,"activeCount":100},[],{"trials":3731,"activeCount":100},[],{"trials":3733,"activeCount":100},[3734],{"nctId":319,"briefTitle":320,"status":308,"phases":3735,"primaryCompletion":322,"completion":322,"start":323,"enrollment":324,"conditions":3736,"interventions":3737},[93],[326,327],[52,329],{"intervention":3739,"totalTrials":96,"cells":3740},"Doxycycline",{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3745,"PHASE3":3747,"PHASE4":3749,"NA":3751},{"trials":3742,"activeCount":100},[],{"trials":3744,"activeCount":100},[],{"trials":3746,"activeCount":100},[],{"trials":3748,"activeCount":100},[],{"trials":3750,"activeCount":100},[],{"trials":3752,"activeCount":100},[3753],{"nctId":3754,"briefTitle":3755,"status":276,"phases":3756,"primaryCompletion":3757,"completion":3757,"start":323,"enrollment":3758,"conditions":3759,"interventions":3760},"NCT03115177","Can Addition of Doxycycline Perioperatively Reduce Propionibacterium Acnes in Shoulder Arthroplasty?",[93],"2017-02",56,[15],[3739,3761],"Cefazolin",{"intervention":3761,"totalTrials":96,"cells":3763},{"EARLY_PHASE1":3764,"PHASE1":3766,"PHASE2":3768,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3765,"activeCount":100},[],{"trials":3767,"activeCount":100},[],{"trials":3769,"activeCount":100},[],{"trials":3771,"activeCount":100},[],{"trials":3773,"activeCount":100},[],{"trials":3775,"activeCount":100},[3776],{"nctId":3754,"briefTitle":3755,"status":276,"phases":3777,"primaryCompletion":3757,"completion":3757,"start":323,"enrollment":3758,"conditions":3778,"interventions":3779},[93],[15],[3739,3761],{"intervention":3781,"totalTrials":96,"cells":3782},"Albuterol Sulfate",{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3787,"PHASE3":3789,"PHASE4":3791,"NA":3793},{"trials":3784,"activeCount":100},[],{"trials":3786,"activeCount":100},[],{"trials":3788,"activeCount":100},[],{"trials":3790,"activeCount":100},[],{"trials":3792,"activeCount":100},[],{"trials":3794,"activeCount":100},[3795],{"nctId":3796,"briefTitle":3797,"status":276,"phases":3798,"primaryCompletion":3799,"completion":3799,"start":3800,"enrollment":866,"conditions":3801,"interventions":3803},"NCT03091504","Evaluation on the Efficacy of Bronchodilator Nebulization Via High Flow Nasal Cannula",[93],"2018-03-31","2017-09-04",[3802],"High Flow Nasal Cannula",[3781],{"intervention":3805,"totalTrials":96,"cells":3806},"Insulin",{"EARLY_PHASE1":3807,"PHASE1":3809,"PHASE2":3811,"PHASE3":3813,"PHASE4":3815,"NA":3817},{"trials":3808,"activeCount":100},[],{"trials":3810,"activeCount":100},[],{"trials":3812,"activeCount":100},[],{"trials":3814,"activeCount":100},[],{"trials":3816,"activeCount":100},[],{"trials":3818,"activeCount":100},[3819],{"nctId":3820,"briefTitle":3821,"status":276,"phases":3822,"primaryCompletion":3823,"completion":3824,"start":3825,"enrollment":3826,"conditions":3827,"interventions":3829},"NCT00920725","Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA",[93],"2007-07","2007-12","2005-01",50,[3828],"Diabetic Ketoacidosis",[3805],{"intervention":3831,"totalTrials":96,"cells":3832},"TOBIpodhaler",{"EARLY_PHASE1":3833,"PHASE1":3835,"PHASE2":3837,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3834,"activeCount":100},[],{"trials":3836,"activeCount":100},[],{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":100},[],{"trials":3842,"activeCount":100},[],{"trials":3844,"activeCount":100},[3845],{"nctId":3846,"briefTitle":3847,"status":308,"phases":3848,"primaryCompletion":3849,"completion":3849,"start":3850,"enrollment":34,"conditions":3851,"interventions":3853},"NCT02038803","Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution",[],"2014-05-07","2013-10-10",[3852],"Cystic Fibrosis",[3831],{"intervention":3855,"totalTrials":96,"cells":3856},"Low dose levodopa",{"EARLY_PHASE1":3857,"PHASE1":3859,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3858,"activeCount":100},[],{"trials":3860,"activeCount":100},[],{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[],{"trials":3868,"activeCount":100},[3869],{"nctId":3870,"briefTitle":3871,"status":276,"phases":3872,"primaryCompletion":3873,"completion":3873,"start":3874,"enrollment":3875,"conditions":3876,"interventions":3877},"NCT04956939","Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease",[],"2021-03-31","2018-07-17",38,[18],[3855,3878],"High dose levodopa",{"intervention":3878,"totalTrials":96,"cells":3880},{"EARLY_PHASE1":3881,"PHASE1":3883,"PHASE2":3885,"PHASE3":3887,"PHASE4":3889,"NA":3891},{"trials":3882,"activeCount":100},[],{"trials":3884,"activeCount":100},[],{"trials":3886,"activeCount":100},[],{"trials":3888,"activeCount":100},[],{"trials":3890,"activeCount":100},[],{"trials":3892,"activeCount":100},[3893],{"nctId":3870,"briefTitle":3871,"status":276,"phases":3894,"primaryCompletion":3873,"completion":3873,"start":3874,"enrollment":3875,"conditions":3895,"interventions":3896},[],[18],[3855,3878],{"intervention":451,"totalTrials":96,"cells":3898},{"EARLY_PHASE1":3899,"PHASE1":3901,"PHASE2":3903,"PHASE3":3905,"PHASE4":3907,"NA":3909},{"trials":3900,"activeCount":100},[],{"trials":3902,"activeCount":100},[],{"trials":3904,"activeCount":100},[],{"trials":3906,"activeCount":100},[],{"trials":3908,"activeCount":100},[],{"trials":3910,"activeCount":100},[3911],{"nctId":443,"briefTitle":444,"status":259,"phases":3912,"primaryCompletion":446,"completion":446,"start":447,"enrollment":100,"conditions":3913,"interventions":3914},[93],[449],[451,272]]